<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Inhaled corticosteroids versus placebo  for stable chronic obstructive pulmonary disease - Yang, IA - 2023 | Cochrane Library</title> <meta content="Inhaled corticosteroids versus placebo  for stable chronic obstructive pulmonary disease - Yang, IA - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002991.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Inhaled corticosteroids versus placebo  for stable chronic obstructive pulmonary disease - Yang, IA - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002991.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002991.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Inhaled corticosteroids versus placebo  for stable chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Ian A Yang" name="citation_author"/> <meta content="Ian.Yang@health.qld.gov.au" name="citation_author_email"/> <meta content="Olivia R Ferry" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="Melissa S Clarke" name="citation_author"/> <meta content="Esther HA Sim" name="citation_author"/> <meta content="GenesisCare Radiation Oncology" name="citation_author_institution"/> <meta content="Kwun M Fong" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD002991.pub4" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/03/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002991.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002991.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002991.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [therapeutic use]; Bronchodilator Agents [adverse effects]; Disease Progression; *Pneumonia [drug therapy]; *Pulmonary Disease, Chronic Obstructive [drug therapy]; Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002991.pub4&amp;doi=10.1002/14651858.CD002991.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="IYhCEbRn";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002991\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002991\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ko","ms","hr","id","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002991.pub4",title:"Inhaled corticosteroids versus placebo\\u00A0 for stable chronic obstructive pulmonary disease",firstPublishedDate:"Mar 27, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002991.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002991.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002991.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002991.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002991.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002991.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002991.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002991.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002991.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002991.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2973 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002991.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-sec-0096"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-sec-0090"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/appendices#CD002991-sec-0101"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/supinfo/CD002991StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/supinfo/CD002991StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Inhaled corticosteroids versus placebo  for stable chronic obstructive pulmonary disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/information#CD002991-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Ian A Yang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/information#CD002991-cr-0005">Olivia R Ferry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/information#CD002991-cr-0006">Melissa S Clarke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/information#CD002991-cr-0007">Esther HA Sim</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002991.pub4/information#CD002991-cr-0008">Kwun M Fong</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/information/en#CD002991-sec-0118">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 March 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002991.pub4">https://doi.org/10.1002/14651858.CD002991.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002991-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002991-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002991-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002991-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002991-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD002991-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002991-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002991-abs-0001" lang="en"> <section id="CD002991-sec-0001"> <h3 class="title" id="CD002991-sec-0001">Background</h3> <p>The role of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) has been the subject of much uncertainty. COPD clinical guidelines currently recommend selective use of ICS. ICS are not recommended as monotherapy for people with COPD, and are only given in combination with long‐acting bronchodilators due to greater efficacy of combination therapy. Incorporating and critiquing newly published placebo‐controlled trials into the monotherapy evidence base may help to resolve ongoing uncertainties and conflicting findings about their role in this population. </p> </section> <section id="CD002991-sec-0002"> <h3 class="title" id="CD002991-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of inhaled corticosteroids, used as monotherapy versus placebo, in people with stable COPD, in terms of objective and subjective outcomes. </p> </section> <section id="CD002991-sec-0003"> <h3 class="title" id="CD002991-sec-0003">Search methods</h3> <p>We used standard, extensive Cochrane search methods. The latest search date was October 2022. </p> </section> <section id="CD002991-sec-0004"> <h3 class="title" id="CD002991-sec-0004">Selection criteria</h3> <p>We included randomised trials comparing any dose of any type of ICS, given as monotherapy, with a placebo control in people with stable COPD. We excluded studies of less than 12 weeks' duration and studies of populations with known bronchial hyper‐responsiveness (BHR) or bronchodilator reversibility. </p> </section> <section id="CD002991-sec-0005"> <h3 class="title" id="CD002991-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our a priori primary outcomes were 1. exacerbations of COPD and 2. quality of life. Our secondary outcomes were 3. all‐cause mortality, 4. lung function (rate of decline of forced expiratory volume in one second (FEV<sub>1</sub>)), 5. rescue bronchodilator use, 6. exercise capacity, 7. pneumonia and 8. adverse events including pneumonia. ]. We used GRADE to assess certainty of evidence. </p> </section> <section id="CD002991-sec-0006"> <h3 class="title" id="CD002991-sec-0006">Main results</h3> <p>Thirty‐six primary studies with 23,139 participants met the inclusion criteria. Mean age ranged from 52 to 67 years, and females were 0% to 46% of participants. Studies recruited across the severities of COPD. Seventeen studies were of duration longer than three months and up to six months and 19 studies were of duration longer than six months. We judged the overall risk of bias as low.  </p> <p>Long‐term (more than six months) use of ICS as monotherapy reduced the mean rate of exacerbations in those studies where pooling of data was possible (generic inverse variance analysis: rate ratio 0.88 exacerbations per participant per year, 95% confidence interval (CI) 0.82 to 0.94; I<sup>2</sup> = 48%, 5 studies, 10,097 participants; moderate‐certainty evidence; pooled means analysis: mean difference (MD) −0.05 exacerbations per participant per year, 95% CI −0.07 to −0.02; I<sup>2</sup> = 78%, 5 studies, 10,316 participants; moderate‐certainty evidence). ICS slowed the rate of decline in quality of life, as measured by the St George's Respiratory Questionnaire (MD −1.22 units/year, 95% CI −1.83 to −0.60; I<sup>2</sup> = 0%; 5 studies, 2507 participants; moderate‐certainty evidence; minimal clinically importance difference 4 points). There was no evidence of a difference in all‐cause mortality in people with COPD (odds ratio (OR) 0.94, 95% CI 0.84 to 1.07; I<sup>2</sup> = 0%; 10 studies, 16,636 participants; moderate‐certainty evidence). Long‐term use of ICS  reduced the rate of decline in FEV<sub>1</sub> in people with COPD (generic inverse variance analysis: MD 6.31 mL/year benefit, 95% CI 1.76 to 10.85; I<sup>2</sup> = 0%; 6 studies, 9829 participants; moderate‐certainty evidence; pooled means analysis: 7.28 mL/year, 95% CI 3.21 to 11.35; I<sup>2</sup> = 0%; 6 studies, 12,502 participants; moderate‐certainty evidence). </p> <p>Adverse events: in the long‐term studies, the rate of pneumonia was increased in the ICS group, compared to placebo, in studies that reported pneumonia as an adverse event (OR 1.38, 95% CI 1.02 to 1.88; I<sup>2</sup> = 55%; 9 studies, 14,831 participants; low‐certainty evidence). There was an increased risk of oropharyngeal candidiasis (OR 2.66, 95% CI 1.91 to 3.68; 5547 participants) and hoarseness (OR 1.98, 95% CI 1.44 to 2.74; 3523 participants). The long‐term studies that measured bone effects generally showed no major effect on fractures or bone mineral density over three years. We downgraded the certainty of evidence to moderate for imprecision and low for imprecision and inconsistency. </p> </section> <section id="CD002991-sec-0007"> <h3 class="title" id="CD002991-sec-0007">Authors' conclusions</h3> <p>This systematic review updates the evidence base for ICS monotherapy with newly published trials to aid the ongoing assessment of their role for people with COPD. Use of ICS alone for COPD likely results in a reduction of exacerbation rates of clinical relevance, probably results in a reduction in the rate of decline of FEV<sub>1</sub> of uncertain clinical relevance and likely results in a small improvement in health‐related quality of life not meeting the threshold for a minimally clinically important difference. These potential benefits should be weighed up against adverse events (likely to increase local oropharyngeal adverse effects and may increase the risk of pneumonia) and probably no reduction in mortality. Though not recommended as monotherapy, the probable benefits of ICS highlighted in this review support their continued consideration in combination with long‐acting bronchodilators. Future research and evidence syntheses should be focused in that area. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002991-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002991-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD002991-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD002991-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002991-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002991-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002991-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD002991-abs-0011">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ko#CD002991-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002991-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD002991-abs-0016">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002991-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002991-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002991-abs-0002" lang="en"> <h3>Inhaled corticosteroids compared with placebo for stable chronic obstructive pulmonary disease (COPD) </h3> <p><b>Key messages</b> </p> <p>Inhaled corticosteroids alone probably reduce flare‐ups of chronic obstructive pulmonary disease (COPD), slow the decline of lung function (measured as the volume of air you can force from your lungs in one second) and lead to small improvements in quality of life. However, they probably also increase the risk of pneumonia and side effects in the mouth and probably do not improve survival. These findings support their continued consideration in combination with other treatments, and future research should be focused in that area. </p> <p><b>What is chronic obstructive pulmonary disease?</b> </p> <p>COPD is the term used for lung problems that cause difficulty breathing. These include chronic bronchitis (long‐lasting inflammation of the lungs) and emphysema (damage to the air sacs of the lungs). Inhaled corticosteroids alone are no longer recommended for people with COPD (known as 'monotherapy'), but they are given with other long‐acting inhaled medicines due to greater effectiveness of combination treatment. Inhaled corticosteroids help to reduce inflammation in the air passages of people with asthma. However, it is uncertain whether these medications are beneficial in people with COPD. </p> <p><b>What did we want to find out?</b> </p> <p>We updated this review of inhaled corticosteroids to help resolve ongoing uncertainties about their role in people with COPD. We analysed their effects on frequency of flare‐ups ('exacerbations'), quality of life, breathing capacity, death rates and side effects such as pneumonia. </p> <p><b>What did we do?</b> </p> <p>We searched medical databases for studies comparing inhaled corticosteroids versus inhaled placebo (pretend treatment) in people with stable COPD. </p> <p><b>What did we find?</b> </p> <p>We included 36 studies, involving 23,139 participants.</p> <p><b>Key results</b> </p> <p>Pooling the data from the trials showed that inhaled corticosteroids were beneficial in reducing the frequency of exacerbations and slowing down the rate of decline in quality of life. There was a long‐term benefit (after six months of treatment) in slowing the rate of decline in breathing capacity. Death rates from any cause were unchanged. Inhaled corticosteroids increased the risk of side effects including thrush (<i>Candida</i>) infection in the mouth, voice hoarseness and pneumonia. </p> <p>In deciding whether to use this treatment, consumers and health professionals should weigh up the benefits against the side effects. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Overall, we have low to moderate confidence in the evidence underlying these findings. We have moderate confidence in the evidence for the findings related to COPD exacerbations, quality of life, breathing capacity, death rates and side effects. This was due to some variation in the data across these studies. We have low confidence in the evidence for pneumonia risk due to variable results across a number of studies. </p> <p><b>How up to date is this evidence?</b> </p> <p>We searched for studies up to October 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002991-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002991-sec-0096"></div> <h3 class="title" id="CD002991-sec-0097">Implications for practice</h3> <section id="CD002991-sec-0097"> <p>In people with chronic obstructive pulmonary disease (COPD), long‐term use of inhaled corticosteroids (ICS) as monotherapy, when compared to placebo, likely reduces the rate of clinically relevant COPD exacerbations and probably slows the rate of decline of lung function (forced expiratory volume in one second (FEV<sub>1</sub>)), which is of unclear clinical relevance. ICS as monotherapy likely results in a small improvement in health‐related quality of life measures without meeting the threshold for a clinically important difference but there is probably no reduction in mortality. The potential benefits must be weighed against the potential adverse events such as a likely increase in the risk of pneumonia and local oropharyngeal candidiasis. </p> <p>Clinicians and patients should balance the small but potential benefits of ICSs in COPD (reduced rate of decline in FEV<sub>1</sub>, reduced exacerbations, reduced rate of decline in quality of life) against the potential adverse effects (oropharyngeal candidiasis and hoarseness, and risk of pneumonia). The certainty of the evidence underlying these findings ranged from low certainty for the outcome of pneumonia to moderate certainty for the remaining outcomes. </p> <p>This systematic review updates the evidence base for ICS monotherapy with newly published trials to aid the ongoing assessment of their role for people with COPD. Though not recommended as monotherapy, the probable benefits of ICS highlighted in this review support their continued consideration in combination with long‐acting bronchodilators.  </p> </section> <h3 class="title" id="CD002991-sec-0098">Implications for research</h3> <section id="CD002991-sec-0098"> <p>This review has raised questions that merit further research.</p> <p> <ol id="CD002991-list-0005"> <li> <p>Which people with COPD should be commenced and maintained on ICSs?</p> </li> <li> <p>What are the clinical and biological factors that predict response to ICSs in people with COPD? </p> </li> <li> <p>What are the long‐term adverse effects of ICSs in people with COPD?</p> </li> </ol> </p> <p>Future primary research and evidence syntheses will be better focused on ICS and long‐acting bronchodilator combination therapies, rather than ICS monotherapy, and for this reason, this will likely be the final Cochrane Review update on ICS as a monotherapy for COPD. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002991-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002991-sec-0008"></div> <div class="table" id="CD002991-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ ICS compared to placebo for adults with stable chronic obstructive pulmonary disease in studies of greater than six months? duration</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ICS compared to placebo for adults with stable chronic obstructive pulmonary disease in studies of greater than six months' duration</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with stable chronic obstructive pulmonary disease<br/><b>Setting:</b> clinical practice/outpatient<br/><b>Intervention:</b> ICS<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ICS</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation rate (exacerbations per participant per year)<br/>follow‐up: mean 95 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean exacerbation rate (exacerbations per participant per year) was <b>0.60</b> exacerbations per patient per year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.05 exacerbations per patient per year lower</b><br/>(0.07 lower to 0.02 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10316<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Of clinical relevance</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (mean change in SGRQ score)<br/>follow‐up: mean 77 weeks<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life (mean change in SGRQ score) was <b>‐0.11</b> points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>1.22 points lower</b><br/>(1.83 lower to 0.6 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2507<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Of uncertain clinical relevance (minimal clinically important difference 4). SGRQ: St George's Respiratory Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in postbronchodilator FEV1 (mL/year)<br/>follow‐up: mean 118 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in postbronchodilator FEV1 (mL/year) was <b>‐49.01</b> mL/year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>7.28 mL/year lower</b><br/>(3.21 lower to 11.35 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12502<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Of uncertain clinical relevance. FEV1: forced expiratory volume in 1 second.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality<br/>follow‐up: mean 113 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b><br/>(61 to 77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.94</b><br/>(0.84 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16636<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not of clinical relevance</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia<br/>follow‐up: mean 106 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>84 per 1000</b><br/>(63 to 111) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.38</b><br/>(1.02 to 1.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14831<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Of clinical relevance</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oropharyngeal candidiasis<br/>follow‐up: mean 114 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b><br/>(37 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.66</b><br/>(1.91 to 3.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5547<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Of clinical relevance</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_428279190022928617" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_428279190022928617</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for imprecision; wide 95% confidence intervals encompassing no effect, benefit and risk.<br/><sup>b</sup> St George's Respiratory Questionnaire (SGRQ) scale from 0 to 100 with higher scores indicating greater impact on health, function and quality of life.<br/><sup>c</sup> Downgraded one level for inconsistency; moderate heterogeneity (overall I2 = 55%) noting that effect sizes were similar between studies. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002991-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002991-sec-0009"></div> <section id="CD002991-sec-0010"> <h3 class="title" id="CD002991-sec-0010">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is a common, chronic lung condition that is characterised by persistent respiratory symptoms and chronic airflow limitation (<a href="./references#CD002991-bbs2-0118" title="Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2023 report. goldcopd.org/2023-gold-report-2/ (accessed prior to 31 October 2022).">GOLD 2023</a>). The pathogenesis of COPD is a combination of mainly small airways and alveolar abnormalities in the lungs, usually secondary to exposure to noxious particles or gases, interacting with host factors (<a href="./references#CD002991-bbs2-0118" title="Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2023 report. goldcopd.org/2023-gold-report-2/ (accessed prior to 31 October 2022).">GOLD 2023</a>; <a href="./references#CD002991-bbs2-0137" title="YangIA , JenkinsCR , SalviS . COPD in never smokers: pathogenesis and implications for prevention and treatment. Lancet Respiratory Medicine2022;10(5):497-511.">Yang 2022</a>). Chronic inflammation has a key role in the pathophysiology of COPD by inducing structural changes such as narrowing of the small airways and destruction of lung parenchyma (<a href="./references#CD002991-bbs2-0108" title="AgustíA , HoggJC . Update on the pathogenesis of chronic obstructive pulmonary disease. New England Journal of Medicine2019;381:1248-56.">Agustí 2019</a>), leading to gas trapping, dynamic hyperinflation and impaired gas exchange, which contribute to the clinical features of COPD (<a href="./references#CD002991-bbs2-0112" title="CelliBR , WedzichaJA . Update on clinical aspects of chronic obstructive pulmonary disease. New England Journal of Medicine2019;381:1257-66.">Celli 2019</a>). </p> <p>Clinical features of COPD include breathlessness on exertion, chronic cough and fatigue. Given that many conditions can result in chronic dyspnoea (<a href="./references#CD002991-bbs2-0116" title="FerryOR , HuangYC , MaselPJ , HamiltonM , FongKM , BowmanRV , McKenzieSC , YangIA . Diagnostic approach to chronic dyspnoea in adults. Journal of Thoracic Disease2019;11(Suppl 17):S2117-28.">Ferry 2019</a>), spirometry is important for confirming the diagnosis of COPD, with the presence of persistent airflow limitation defined as a postbronchodilator forced expiratory volume in one second (FEV<sub>1</sub>)/forced vital capacity (FVC) ratio of less than 0.70 (<a href="./references#CD002991-bbs2-0118" title="Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2023 report. goldcopd.org/2023-gold-report-2/ (accessed prior to 31 October 2022).">GOLD 2023</a>). The natural history of COPD often follows a decline in lung function associated with progressive symptomatology. Exacerbations of COPD are common, triggered by bacterial or viral respiratory tract infections or environmental exposures (<a href="./references#CD002991-bbs2-0124" title="KoFW , ChanKP , HuiDS , GoddardJR , ShawJG , ReidDW , YangIA . Acute exacerbation of chronic obstructive pulmonary disease. Respirology2016;21(7):1152-65.">Ko 2016</a>). Preventing exacerbations in COPD is important due to their negative impact on quality of life, lung function decline and overall prognosis (<a href="./references#CD002991-bbs2-0118" title="Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2023 report. goldcopd.org/2023-gold-report-2/ (accessed prior to 31 October 2022).">GOLD 2023</a>). </p> <p>COPD is associated with a high burden of disease with significant mortality and morbidity. There are health system and economic impacts arising from care of people with COPD, with exacerbations frequently requiring hospitalisation. COPD is not only associated with increased mortality but also with impairment in quality of life, particularly with disease progression and exacerbations (<a href="./references#CD002991-bbs2-0118" title="Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2023 report. goldcopd.org/2023-gold-report-2/ (accessed prior to 31 October 2022).">GOLD 2023</a>). </p> </section> <section id="CD002991-sec-0011"> <h3 class="title" id="CD002991-sec-0011">Description of the intervention</h3> <p>Current management approaches for COPD, both non‐pharmacological and pharmacological, focus on reducing symptoms and reducing risk of exacerbations (<a href="./references#CD002991-bbs2-0118" title="Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2023 report. goldcopd.org/2023-gold-report-2/ (accessed prior to 31 October 2022).">GOLD 2023</a>). Non‐pharmacological treatment includes smoking cessation, pulmonary rehabilitation, vaccination and self‐management action plans. Pharmacological treatment includes inhaled therapies: long‐acting muscarinic receptor antagonists (LAMA), long‐acting beta<sub>2</sub>‐agonists (LABA), inhaled corticosteroids (ICS) and combinations of these. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy recommends consideration of initial use of ICS, combined with a LABA, as one of the options for people with COPD with exacerbations and higher blood eosinophil counts (<a href="./references#CD002991-bbs2-0118" title="Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2023 report. goldcopd.org/2023-gold-report-2/ (accessed prior to 31 October 2022).">GOLD 2023</a>). If dyspnoea or exacerbations need further treatment, then stepping up to ICS/LABA/LAMA is a treatment option. Other national COPD guidelines offer similar recommendations  (<a href="./references#CD002991-bbs2-0113" title="DabscheckE , GeorgeJ , HerrmannK , McDonaldCF , McDonaldVM , McNamaraRJ , O’BrienM , SmithBJ , ZwarNA , YangIA . COPD-X Australian guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2022 update. Medical Journal of Australia2022;217(8):415-23.">Dabscheck 2022</a>). ICS as a monotherapy is no longer recommended in clinical guidelines due to the greater efficacy of combination ICS and long‐acting bronchodilators (LAMAs or LABAs) (<a href="./references#CD002991-bbs2-0118" title="Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2023 report. goldcopd.org/2023-gold-report-2/ (accessed prior to 31 October 2022).">GOLD 2023</a>; <a href="./references#CD002991-bbs2-0126" title="NanniniLJ , PooleP , MilanSJ , KestertonA . Combined corticosteroid and long-acting beta2-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD006826. [DOI: 10.1002/14651858.CD006826.pub2]">Nannini 2013</a>). </p> </section> <section id="CD002991-sec-0012"> <h3 class="title" id="CD002991-sec-0012">How the intervention might work</h3> <p>ICS target the inflammatory component of COPD. By reducing airway inflammation, the aim of ICS is to decrease inflammation‐driven structural changes in the airways, in order to reduce respiratory symptoms, slow disease progression and decrease risk of exacerbations. ICS are glucocorticoids that are delivered as fine or ultrafine particles from inhalers to reach the airways. ICS, as glucocorticoids, exert their action via genomic and non‐genomic mechanisms (<a href="./references#CD002991-bbs2-0135" title="YangIA , ShawJG , GoddardJR , ClarkeMS , ReidDW . Use of inhaled corticosteroids in COPD: improving efficacy. Expert Review of Respiratory Medicine2016;10(3):339-50.">Yang 2016</a>). The genomic pathways involve binding to intracellular glucocorticoid receptors to activate anti‐inflammatory gene expression and deactivate pro‐inflammatory gene expression. The non‐genomic pathways involve signalling through membrane‐associated receptors and direct activation of signalling pathways. The immunosuppressive effects of ICS on host defence mechanisms, including macrophages and epithelial cells, could also potentially lead to increased risk of respiratory infection, especially pneumonia.  </p> </section> <section id="CD002991-sec-0013"> <h3 class="title" id="CD002991-sec-0013">Why it is important to do this review</h3> <p>ICS therapy has the potential to benefit people with COPD by improving quality of life, slowing disease progression and reducing exacerbation rates, although the magnitude of these benefits remains uncertain. Furthermore, safety concerns have been raised regarding the adverse effects of ICS, including the risk of pneumonia. Therefore, the exact role of ICS usage for people with COPD remains under discussion. ICS are no longer recommended as monotherapy for people with COPD but in combination with long‐acting bronchodilators due to the greater effectiveness when used in combination. Incorporating and critiquing newly published placebo‐controlled trials into the monotherapy evidence base may help to resolve ongoing uncertainties and conflicting findings about their role in this population. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002991-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002991-sec-0014"></div> <p>To evaluate the benefits and harms of inhaled corticosteroids, used as monotherapy versus placebo, in people with stable patients with COPD, in terms of objective and subjective outcomes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002991-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002991-sec-0015"></div> <section id="CD002991-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002991-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered all published and unpublished randomised controlled trials (RCTs) of ICS in people with COPD. Placebo‐controlled trials with random allocation and double‐blinding were included. We preferred trials analysed on an intention‐to‐treat basis. We considered parallel‐group, cross‐over (using only data from the period before cross‐over) and cluster design studies. We included studies with a minimum duration of treatment of 12 weeks to enable sufficient time for meaningful change in outcome data. In this updated review we excluded studies with a study duration of less than 12 weeks or study participants with bronchodilator reversibility or BHR. </p> </section> <section id="CD002991-sec-0018"> <h4 class="title">Types of participants</h4> <p>We reviewed studies of adults of either gender, regardless of smoking history, with COPD defined as progressive chronic airflow limitation, consistent with COPD diagnostic criteria at the time of the study. Participants were in a clinically stable state at the start of the study, without recent exacerbation, hospitalisation or need for antibiotics or systemic corticosteroids in a defined period (usually six weeks) prior to study commencement. Participants did not have clinical features of asthma. We excluded studies that recruited people with acute bronchodilator reversibility to short‐acting beta<sub>2</sub>‐agonists or people with BHR to reduce the likelihood of including people with an asthma phenotype. </p> </section> <section id="CD002991-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies of ICS as monotherapy administered by inhalation devices including metered‐dose inhaler, dry powder inhaler or spacer devices versus placebo. We excluded studies delivering ICS by nebuliser to reflect real world practice and people with stable COPD. We excluded studies of ICS versus placebo with long‐acting bronchodilators as a fixed co‐intervention in each group. We excluded studies of ICS in combination with any other LABA or LAMA; however, short‐acting bronchodilator use was allowed. </p> </section> <section id="CD002991-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We analysed outcome data in two groups by three‐ to six‐month study duration and greater than six‐month duration due to variability in outcome measures.  </p> <section id="CD002991-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD002991-list-0001"> <li> <p>Exacerbations of COPD</p> </li> <li> <p>Quality of life </p> </li> </ol> </p> </section> <section id="CD002991-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD002991-list-0002"> <li> <p>All‐cause mortality</p> </li> <li> <p>Lung function (rate of decline of FEV<sub>1</sub>) </p> </li> <li> <p>Rescue bronchodilator use</p> </li> <li> <p>Exercise capacity</p> </li> <li> <p>Pneumonia</p> </li> <li> <p>Adverse events: oropharyngeal adverse de effects (throat irritation, oropharyngeal candidiasis), skin bruising, hypothalamic‐pituitary‐adrenal (HPA) axis function, fractures </p> </li> </ol> </p> </section> </section> </section> <section id="CD002991-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002991-sec-0024"> <h4 class="title">Electronic searches</h4> <p>In the original 2007 review, we examined and combined RCTs of ICSs in adults with COPD from 1966 to October 2006. The 2011 update included trials from October 2006 to July 2011. This 2022 update includes trials from July 2011 to October 2022. </p> <p>We searched the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, CINAHL, AMED and PsycINFO, and handsearching of respiratory journals and meeting abstracts (see Appendix 1 for more details). We used the search strategy in <a href="./appendices#CD002991-sec-0102">Appendix 1</a> to identify trials from the Register. We conducted additional searches of CENTRAL, ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="https://trialsearch.who.int" target="_blank">trialsearch.who.int</a>). See <a href="./appendices#CD002991-sec-0102">Appendix 1</a> for these search strategies. Searches were conducted up to 31 October 2022 with no restrictions on language or type of publication. </p> </section> <section id="CD002991-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the bibliographies of each included study for additional relevant studies. We undertook additional searches of manufacturers' websites in order to identify unpublished data. </p> </section> </section> <section id="CD002991-sec-0026"> <h3 class="title" id="CD002991-sec-0026">Data collection and analysis</h3> <section id="CD002991-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (IY, OF) independently assessed for relevance of the titles and, where available, retrieved abstracts of all trials identified by the search strategy. We retrieved all relevant or potentially relevant articles in full. We categorised these articles as relevant (met the inclusion criteria for considering studies) or not relevant (did not meet the inclusion criteria for considering studies). We resolved disagreements about relevance by consensus. </p> </section> <section id="CD002991-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (IY, ES and TL) extracted data from included studies for the original 2007 review. Two review authors (IY, MC) extracted data from included studies for the 2012 update and two review authors (IY, OF) extracted data from included studies for this 2022 update. </p> </section> <section id="CD002991-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (IY, OF) independently assessed the quality of all relevant trials, using the Cochrane RoB 1 tool, to assess risk of bias (<a href="./references#CD002991-bbs2-0120" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). The risk of bias was assessed across the following domains. </p> <p> <ol id="CD002991-list-0003"> <li> <p>Random sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessment (detection bias)</p> </li> <li> <p>Blinding (performance bias and detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selective reporting (reporting bias)</p> </li> <li> <p>Other bias</p> </li> </ol> </p> <p>We judged each item as having a high, low or unclear risk of bias.</p> </section> <section id="CD002991-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>If appropriate data for mean, standard deviation (SD) and number of participants in each treatment and placebo arm were available, we combined data from trials using Review Manager Web, generating a mean difference (MD) and 95% confidence interval (CI) (<a href="./references#CD002991-bbs2-0127" title="Review Manager Web (RevMan Web). Version 4.15.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2020</a>). We used an MD for continuous variables. We summarised proportional outcomes, such as proportion of participants who improved, using an odds ratio (OR), with 95% CI. We used the Mantel‐Haenszel method to combine estimates of the ORs. </p> </section> <section id="CD002991-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>For dichotomous outcomes, we counted participants as the unit of analysis to avoid double counting. Where trials presented data as rate ratios (e.g. exacerbation data), we analysed these using generic inverse variance. </p> </section> <section id="CD002991-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>Wherever possible, we sought missing data in the publication from the authors by correspondence (email, fax or letter). In situations where this was not possible, then this was taken into consideration for the risk of bias assessment. </p> </section> <section id="CD002991-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We performed tests for heterogeneity using Review Manager Web (<a href="./references#CD002991-bbs2-0127" title="Review Manager Web (RevMan Web). Version 4.15.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2020</a>). We also applied a random‐effects model as part of sensitivity analysis. </p> </section> <section id="CD002991-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We created a funnel plot of studies if we included 10 or more trials in any single meta‐analysis comparison. </p> </section> <section id="CD002991-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We used a fixed‐effect MD for continuous variables. If data were reported on different metrics, we planned to use a standardised mean difference (SMD), which expresses differences as SD units. </p> </section> <section id="CD002991-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The treatment periods were separated empirically into short term (three to six months) and long term (greater than six months) based on the study designs employed. We banded ICS dose by equivalent beclomethasone dosage to indicate high (1000 µg or greater) or low ICS (less than 1000 µg) dosage subgroups. </p> </section> <section id="CD002991-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform a sensitivity analysis by excluding studies at high risk of bias in the primary analyses. </p> </section> <section id="CD002991-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created summary of findings tables for the following outcomes for studies of duration greater than six months: change in post‐bronchodilator FEV<sub>1</sub>, exacerbation rate, quality of life, all‐cause mortality, pneumonia and oropharyngeal candidiasis. We assessed study design, risk of bias, inconsistency, indirectness, imprecision for the results for these outcomes, and determined the certainty of the evidence for each outcome using the GRADE Working Group grades of evidence: high certainty, moderate certainty, low certainty and very low certainty. We prepared the summary of findings table using GRADEpro GDT software (<a href="./references#CD002991-bbs2-0119" title="GRADEpro GDT. Version accessed January 2022. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). We provided justification for downgrading of certainty of evidence using footnotes. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002991-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002991-sec-0039"></div> <section id="CD002991-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD002991-sec-0041"> <h4 class="title">Results of the search</h4> <p>We retrieved and assessed 2205 abstracts in the original 2007 review. In the 2012 update, we retrieved and assessed 339 additional abstracts (see <a href="#CD002991-tbl-0002">Table 1</a>: 'Search history detail'), with 36 studies meeting the inclusion criteria; of these, eight were new studies not previously included. In this 2022 update, we retrieved and assessed a further 1347 abstracts after removal of duplicates (see <a href="#CD002991-tbl-0002">Table 1</a>: 'Search history detail'). We reviewed the full‐text of five studies; of these, we included four new studies and excluded one. As per our updated exclusion criteria, we excluded 22 studies included in the previous reviews due to study duration of less than 12 weeks (18 studies: <a href="./references#CD002991-bbs2-0040" title="AuffarthB , PostmaDS , deMonchyJG , van derMarkTW , BoorsmaM , KoeterGH . Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease. Thorax1991;46(5):372-7. ">Auffarth 1991</a>; <a href="./references#CD002991-bbs2-0044" title="BrightlingCE , McKennaS , HargadonB , BirringS , GreenR , SivaR , et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax2005;60(3):193-8. ">Brightling 2005</a>; <a href="./references#CD002991-bbs2-0050" title="CulpittSV , MaziakW , LoukidisS , NightingaleJA , MatthewsJL , BarnesPJ . Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1999;160(5 Pt 1):1635-9. ">Culpitt 1999</a>; <a href="./references#CD002991-bbs2-0057" title="FerreiraIM , HazariMS , GutierrezC , ZamelN , ChapmanKR . Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: effects of inhaled beclomethasone. American Journal of Respiratory and Critical Care Medicine2001;164(6):1012-5. ">Ferreira 2001</a>; <a href="./references#CD002991-bbs2-0058" title="FerreiraIM , SandriniA , ZamelN , BalterM , ChapmanKR . Effects of inhaled fluticasone propionate (FP) on Exhaled Nitric Oxide (ENO), functional exercise capacity and quality of life in stable patients with COPD. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:B024 Poster 404. ">Ferreira 2003</a>; <a href="./references#CD002991-bbs2-0059" title="GuenetteJA , RaghavanN , Harris-McAllisterV , PrestonME , WebbKA , O'DonnellDE . Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD. Respiratory Medicine2011;105(12):1836-45. [1532-3064: (Electronic)] ">Guenette 2011</a>; <a href="./references#CD002991-bbs2-0063" title="Llewellyn-JonesCG , HarrisTA , StockleyRA . Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. American Journal of Respiratory and Critical Care Medicine1996;153(2):616-21. ">Llewellyn‐Jones 1996</a>; <a href="./references#CD002991-bbs2-0064" title="LoppowD , SchleissMB , KanniessF , TaubeC , JorresRA , MagnussenH . In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respiratory Medicine2001;95(2):115-21. ">Loppow 2001</a>; <a href="./references#CD002991-bbs2-0070" title="NishimuraK , KoyamaH , IkedaA , TsukinoM , HajiroT , MishimaM , et al. The effect of high-dose inhaled beclomethasone dipropionate in patients with stable COPD. Chest1999;115(1):31-7. ">Nishimura 1999</a>; <a href="./references#CD002991-bbs2-0075" title="RobertsonAS , GoveRI , WielandGA , BurgePS . A double-blind comparison of oral prednisolone 40 mg/day with inhaled beclomethasone dipropionate 1500 ug/day in patients with adult onset chronic obstructive airways disease. European Journal of Respiratory Diseases1986;146:565-9. ">Robertson 1986</a>; <a href="./references#CD002991-bbs2-0077" title="RutgersSR , KoeterGH , van derMarkTW , PostmaDS . Short-term treatment with budesonide does not improve hyperresponsiveness to adenosine 5'-monophosphate in COPD. American Journal of Respiratory and Critical Care Medicine1998;157(3 Pt 1):880-6. ">Rutgers 1998</a>; <a href="./references#CD002991-bbs2-0082" title="SinDD , LacyP , YorkE , ManSFP . Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2004;170(7):760-5. ">Sin 2004</a>; <a href="./references#CD002991-bbs2-0083" title="SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008;177(11):1207-14. ">Sin 2008</a>; <a href="./references#CD002991-bbs2-0085" title="ThompsonAB , MuellerMB , HeiresAJ , BohlingTL , DaughtonD , YanceySW , et al. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. American Review of Respiratory Disease1992;146(2):389-95. [MEDLINE: 93143171]">Thompson 1992</a>; <a href="./references#CD002991-bbs2-0097" title="WeinerP , WeinerM , AzgadY , ZamirD . Inhaled budesonide therapy for patients with stable COPD. Chest1995;108(6):1568-71. ">Weiner 1995</a>; <a href="./references#CD002991-bbs2-0099" title="WeinerP , WeinerM , RabnerM , WaizmanJ , MagadleR , ZamirD . The response to inhaled and oral steroids in patients with stable chronic obstructive pulmonary disease. Journal of Internal Medicine1999;245(1):83-9. ">Weiner 1999</a>; <a href="./references#CD002991-bbs2-0035" title="WeirDC , BaleGA , BrightP , Sherwood BurgeP . A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy Supplement1999;29(2):125-8. ">Weir 1999</a>; <a href="./references#CD002991-bbs2-0102" title="WempeJB , PostmaDS , BreederveldN , KortE , van derMarkTW , KoeterGH . Effects of corticosteroids on bronchodilator action in chronic obstructive lung disease. Thorax1992;47(8):616-21. ">Wempe 1992</a>), or study participants with bronchodilator reversibility or BHR (four studies: <a href="./references#CD002991-bbs2-0043" title="Boothman-BurrellD , DelanySG , FlanneryEM , HancoxRJ , TaylorDR . The efficacy of inhaled corticosteroids in the management of non asthmatic chronic airflow obstruction. New Zealand Medical Journal1997;110(1053):370-3. ">Boothman‐Burrell 1997</a>; <a href="./references#CD002991-bbs2-0086" title="ThompsonWH , CarvalhoP , SouzaJP , CharanNB . Controlled trial of inhaled fluticasone propionate in moderate to severe COPD. Lung2002;180(4):191-201. ">Thompson 2002</a>; <a href="./references#CD002991-bbs2-0092" title="vanGrunsvenP , SchermerT , AkkermansR , AlbersM , vanden BoomG , vanSchayckO , et al. Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study. Respiratory Medicine2003;97(12):1303-12. ">van Grunsven 2003</a>; <a href="./references#CD002991-bbs2-0094" title="VerhoevenGT , GarreldsIM , HoogstedenHC , ZijlstraFJ . Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators of Inflammation2001;10(1):21-6. VerhoevenGT , HegmansJP , MulderPG , BogaardJM , HoogstedenHC , Prins, JB. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax2002;57(8):694-700. VerhoevenGT , WijkhuijsAJ , HooijkaasH , HoogstedenHC , SluiterW . Effect of an inhaled glucocorticoid on reactive oxygen species production by bronchoalveolar lavage cells from smoking COPD patients. Mediators of Inflammation2000;9(2):109-13. ">Verhoeven 2002</a>). A total of 36 studies (compared to 55 studies in the 2012 review) met inclusion criteria for this systematic review. For full details on individual studies, see the <a href="./references#CD002991-sec-0124" title="">Characteristics of included studies</a> table. For a study flow diagram, see <a href="#CD002991-fig-0001">Figure 1</a>. </p> <div class="table" id="CD002991-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Search history detail</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Year</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Abstracts retrieved</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to and including 1999</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1340</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009–2010</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012–2013</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2015–2016</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2017</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2018</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2019–2021</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>625</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2021 to 31 October 2022</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>324</p> </td> </tr> </tbody> </table> </div> <div class="figure" id="CD002991-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram. BHR: bronchial hyper‐responsiveness." data-id="CD002991-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram. BHR: bronchial hyper‐responsiveness.</p> </div> </div> </div> </section> <section id="CD002991-sec-0042"> <h4 class="title">Included studies</h4> <section id="CD002991-sec-0043"> <h5 class="title">Study design</h5> <p>All studies were randomised, placebo‐controlled trials described as either double‐blind or double‐dummy. One study was of a cross‐over design with all remaining studies conducted as a parallel‐group design (<a href="./references#CD002991-bbs2-0014" title="JohnM , BosseS , OltmannsU , SchumacherA , WittC . Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respiratory Medicine2005;99(11):1418-24. JohnM , BosseS , SchumacherA , OltmannsU , WittC . Effects of inhaled beclomethasone HFA 134 (qvar/ventoiair) on health related quality of life in patients with chronic obstructive pulmonary disease [Abstract]. In: American Thoracic Society International Conference; 2005 May 20-25; San Diego. 2005:Poster A43. ">John 2005</a>).  </p> </section> <section id="CD002991-sec-0044"> <h5 class="title">Participants</h5> <p>The studies recruited 23,139 participants with COPD (compared to 13,139 in the original 2007 review and 16,154 in the 2012 updated review). Mean age ranged from 52 to 67 years, and % of women ranged from 0% to 46%. More‐recent trials tended to use international criteria for the definition of COPD, and the remaining studies based their definition of COPD on lung function and smoking history (see <a href="./references#CD002991-sec-0124" title="">Characteristics of included studies</a> table). Most studies excluded people who had an exacerbation within six to eight weeks prior to recruitment. Of note, the inclusion criteria of the SUMMIT trial required a previous history or increased risk of cardiovascular disease (<a href="./references#CD002991-bbs2-0034" title="VestboJ , AndersonJA , BrookRD , CalverleyPM , CelliBR , CrimC , et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet2016;387:1817-26. ">Vestbo 2016</a>). </p> </section> <section id="CD002991-sec-0045"> <h5 class="title">Interventions</h5> <p>All studies were placebo‐controlled. The studies used six types of ICS: BUD (budesonide), BDP (beclomethasone dipropionate), FP (fluticasone propionate), FF (fluticasone furoate), TAA (triamcinolone acetonide) and MF (mometasone furoate). Study durations were: </p> <p> <ol id="CD002991-list-0004"> <li> <p>three to six months in 17 studies (<a href="./references#CD002991-bbs2-0001" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477-82. ">Bourbeau 1998</a>; <a href="./references#CD002991-bbs2-0002" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007;62(11):938-43. ">Bourbeau 2007</a>; <a href="./references#CD002991-bbs2-0009" title="FCO30002. A multicentre, randomised, placebo-controlled, double-blind comparison with 3 parallel groups to investigate the efficacy and safety of inhaled glucocorticoid fluticasone (500 μg bd via Diskus™) vs. oral glucocorticoid therapy vs. placebo in subjects with chronic obstructive airway disease (COPD) under therapy with salmeterol (50 μg bd). GlaxoSmithKline Clinical Trial Register2005. ">GSK FCO30002</a>; <a href="./references#CD002991-bbs2-0010" title="FLTA3025. A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250mcg BID, 500mcg BID, and placebo BID via the DISKUS in subjects with chronic obstructive pulmonary disease (COPD). www.gsk-studyregister.com/en/trial-details/?id=FLTA3025 (first received 8 August 1998). ">GSK FLTA3025</a>; <a href="./references#CD002991-bbs2-0012" title="GSK SFCA3007. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3007 (first received 10 November 1998). HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834-43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine2001;163(Suppl 5):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22(Suppl 45):P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. In: US COPD Coalition National COPD Conference 2003; Nov 14-15, Arlington. 2003:1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P429. ">GSK SFCA3007</a>; <a href="./references#CD002991-bbs2-0013" title="GizyckiMJ , HattotuwaKL , BarnesN , JefferyPK . Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax2002;57(9):799-803. HattotuwaKL , GizyckiMJ , AnsariTW , JefferyPK , BarnesNC . The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;165(12):1592-9. ">Hattotuwa 2002</a>; <a href="./references#CD002991-bbs2-0014" title="JohnM , BosseS , OltmannsU , SchumacherA , WittC . Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respiratory Medicine2005;99(11):1418-24. JohnM , BosseS , SchumacherA , OltmannsU , WittC . Effects of inhaled beclomethasone HFA 134 (qvar/ventoiair) on health related quality of life in patients with chronic obstructive pulmonary disease [Abstract]. In: American Thoracic Society International Conference; 2005 May 20-25; San Diego. 2005:Poster A43. ">John 2005</a>; <a href="./references#CD002991-bbs2-0016" title="KerwinEM , Scott-WilsonC , SanfordL , RennardS , AgustiA , BarnesN , et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respiratory Medicine2013;107:560-9. ">Kerwin 2013</a>; <a href="./references#CD002991-bbs2-0018" title="LaptsevaIM , LaptsevaEA , BorshchevskyVV , GurevichG , KalechitsO . Inhaled budesonide in the management of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):244s. ">Laptseva 2002</a>; <a href="./references#CD002991-bbs2-0020" title="GSK SFCA3006. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3006 (first accessed 24 September 1998). MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). www.abstracts2view.com (accessed prior to 9 September 2022). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084-91. ">Mahler 2002</a>; <a href="./references#CD002991-bbs2-0021" title="MartinezFJ , BosciaJ , FeldmanG , Scott-WilsonC , KilbrideS , FabbriL , et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respiratory Medicine2013;107:550-9. ">Martinez 2013</a>; <a href="./references#CD002991-bbs2-0022" title="MiriciA , BektasY , OzbakisG , ErmanZ . Effect of inhaled corticosteroids on respiratory function tests and airway inflammation in stable chronic obstructive pulmonary disease. Clinical Drug Investigation2001;21(12):835-42. ">Mirici 2001</a>; <a href="./references#CD002991-bbs2-0023" title="OzolD , AysanT , SolakZA , MogulkocN , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respiratory Medicine2005;99(12):1494-500. ">Ozol 2005</a>; <a href="./references#CD002991-bbs2-0024" title="FLIT97. A multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000µg daily with placebo in chronic obstructive pulmonary disease. ctr.gsk.co.uk2005. PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773-80. ">Paggiaro 1998</a>; <a href="./references#CD002991-bbs2-0028" title="SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respiratory Medicine1999;93(10):715-8. ">Senderovitz 1999</a>; <a href="./references#CD002991-bbs2-0032" title="TashkinDP , DohertyDE , KerwinE , Matiz-BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73-86. ">Tashkin 2012</a>; <a href="./references#CD002991-bbs2-0036" title="YildizF , BasyigitI , YildirimE , BoyaciH , IlgazliA . Does addition of inhaled steroids to combined bronchodilator therapy affect health status in patients with COPD?Respirology2004;9(3):352-5. ">Yildiz 2004</a>); </p> </li> <li> <p>longer than six months in 19 studies (<a href="./references#CD002991-bbs2-0003" title="BaleG , Martinez-CamblorP , BurgePS , SorianoJB . Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468-72. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297-303. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654-8. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659-64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW . Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350. D'UrzoAD , CalverleyPM . Withdrawal of treatment in the ISOLDE study [letter]. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161-6. JonesPW , WillitsLR , BurgePS , CalverleyPM . Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68-73. SpencerS , CalverleyPM , BurgePS , JonesPW . Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122-8. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698-702. ">Burge 2000</a>; <a href="./references#CD002991-bbs2-0004" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449-56. CalverleyPM , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. www.abstracts2view.com (accessed prior to 11 March 2022). CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). GSK-SFCB3024. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. www.gsk-studyregister.com/en/trial-details/?id=SFCB3024 (first received 1 August 1998). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004:D22 Poster 503. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference [A39] [Poster K39]. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPM , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003:P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist2004;45(6):727-8. PauwelsRA , CalverlyPM , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1569]. PauwelsRA , VestboJ , CalverleyPM , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619-37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPM , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301-4. VestboJ , PauwelsRA , CalverleyPM , JonesPW , PrideNB , GulsvikA . Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045-50. ">Calverley 2003a</a>; <a href="./references#CD002991-bbs2-0005" title="BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912-9. CalverleyPM , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P436. CalverleyPM , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. CalverleyPM , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:B024 Poster 418. CalverleyPM , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:D092 Poster 211. CalverleyPM , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. In: American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego. 2005. CalverleyPM , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. In: American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando. 2004. HalpinDMG , LarssonT , CalverleyPM . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. In: American Thoracic Society 2005 International Conference; May 20-25; San Diego. 2005. JonesPW , StåhlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [Abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health-related quality of life in patients with COPD. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365-75. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14-21. ">Calverley 2003b</a>; <a href="./references#CD002991-bbs2-0006" title="CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppl 5):A149 [PS-3-8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719-25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775-89. CalverleyPM , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , VestboJ , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD Health (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O-9-2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. San Francisco, California, USA, 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317-22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332-8. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB . Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456-65. FergusonGT , CalverleyPM , AndersonJA . The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. GSK-SCO30003. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.gsk-studyregister.com/en/trial-details/?id=SCO30003#documents-section (first received 7 September 2000). JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research2009;10:59. MehtaRS , KathmanSJ , Daley-YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long-term twice-daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:Poster #A41. The TORCH study group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206-10. ">Calverley 2007</a>; <a href="./references#CD002991-bbs2-0007" title="CalverleyP , PauwelsR , NieminemM , StryszakP , StaudingerH , LeeT . Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003:P155. CalverleyPM , RennardS , NelsonHS , KarpelJP , AbbateEH , StryszakP , et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respiratory Research2008;9:73. [1465-993X: (Electronic)] NelsonH , KarpelJP , StaudingerH , BusseWW . Mometasone furoate dry powder inhaler (MF-DPI) improves FEV1, symptoms, quality of life and reduces exacerbations in patients with COPD. Chest2004;236(4 Suppl):709s-10s. ">Calverley 2008</a>; <a href="./references#CD002991-bbs2-0008" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. ">Derenne 1995</a>; <a href="./references#CD002991-bbs2-0011" title="GSK-SCO30002. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. www.gsk-studyregister.com/en/trial-details/?id=SCO30002 (first received 11 January 2006). ">GSK‐SCO30002</a>; <a href="./references#CD002991-bbs2-0015" title="KapteinAA , BrandPL , DekkerFW , KerstjensHA , PostmaDS , SluiterHJ . Quality-of-life in a long-term multicentre trial in chronic nonspecific lung disease: assessment at baseline. The Dutch CNSLD Study Group. European Respiratory Journal1993;6(10):1479-84. KerstjensHA , BrandPL , HughesMD , RobinsonNJ , PostmaDS , SluiterHJ , et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. New England Journal of Medicine1992;327(20):1413-9. KerstjensHA , BrandPL , QuanjerPH , van derBruggen-BogaartsBA , KoeterGH , et al. Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group. Thorax1993;48(7):722-9. KerstjensHA , BrandPL , deJongPM , KoeterGH , PostmaDS . Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group. Thorax1994;49(11):1109-15. KerstjensHA , OverbeekSE , SchoutenJP , BrandPL , PostmaDS . Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. European Respiratory Journal1993;6(6):868-76. KerstjensHA , PostmaDS , vanDoormaalJJ , vanZantenAK , BrandPL , DekhuijzenPN , et al. Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group. Thorax1994;49(7):652-6. KerstjensHA , SchoutenJP , BrandPL , SchoonbroodDF , SterkPJ , PostmaDS . Importance of total serum IgE for improvement in airways hyperresponsiveness with inhaled corticosteroids in asthma and chronic obstructive pulmonary disease. The Dutch CNSLD Study Group. American Journal of Respiratory and Critical Care Medicine1995;151(2 Pt 1):360-8. OverbeekSE , KerstjensHA , BogaardJM , MulderPG , PostmaDS . Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? The Dutch CNSLD Study Group. The Dutch Chronic Nonspecific Lung Disease Study Groups. Chest1996;110(1):35-41. Rutten-van MolkenMP , vanDoorslaerEK , JansenMC , KerstjensHA , RuttenFF . Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1995;151(4):975-82. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. ">Kerstjens 1992</a>; <a href="./references#CD002991-bbs2-0017" title="LapperreTS , Snoeck-StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517-27. ">Lapperre 2009</a>; <a href="./references#CD002991-bbs2-0019" title="AnthonisenNR , ConnettJC , MurrayRP . Smoking and lung function of Lung Health Study participants after 11 years. American Journal of Respiratory and Critical Care Medicine2002;166(5):675-9. EichenhornMS , WiseRA , MadhokTC , GeraldLB , BaileyWC , TashkinDP , et al. Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest2003;124(1):57-62. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New England Journal of Medicine2000;343(26):1902-9. ScanlonPD , ConnettJE , WiseRA , TashkinDP , MadhokT , SkeansM , et al. Loss of one density with inhaled triamcinolone in Lung Health Study II. American Journal of Respiratory and Critical Care Medicine2004;170(12):1302-9. TashkinDP , MurrayHE , SkeansM , MurrayRP . Skin manifestations of inhaled corticosteroids in COPD patients. Chest2004;126(4):1123-33. ">LHS 2000</a>; <a href="./references#CD002991-bbs2-0025" title="JohnellO , PauwelsR , Löfdahl C-G, LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. European Respiratory Journal2002;19(6):1058-63. LofdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467-72. PauwelsRA , LofdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of Medicine1999;340(25):1948-53. PauwelsRA , LofdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254-61. ">Pauwels 1999</a>; <a href="./references#CD002991-bbs2-0026" title="RenkemaTE , SchoutenJP , KoeterGH , PostmaDS . Effects of long-term treatment with corticosteroids in COPD. Chest1996;109(5):1156-62. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. ">Renkema 1996</a>; <a href="./references#CD002991-bbs2-0027" title="ChavannesNH , SchermerTR , WoutersEF , AkkermansRP , DekhuijzenRP , MurisJW , et al. Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International Journal of COPD2009;4:431-6. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103(4):542-51. ">Schermer 2009</a>; <a href="./references#CD002991-bbs2-0029" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , MaltbaekN , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD2009;6(2):104-11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD2011;8(1):2-7. ">Shaker 2009</a>; <a href="./references#CD002991-bbs2-0030" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii43. CalverleyPM , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverleyPM . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57 (Suppl 3):S145. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. In: BTS Winter Meeting, 2002 Dec 4-6; London. 2002:S143. CampbellLW , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate-severe COPD. In: BTS Winter Meeting, 2002 Dec 4-6; London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night-time awakenings in moderate-severe COPD: results from symptoms and night-time awakenings in moderate to severe COPD: results from a 1-year study. European Respiratory Journal2002;20(Suppl 38):242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004:D22 Poster 525. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20(Suppl 38):250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1-year study of patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20(Suppl 38):242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14-21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21:74-81. SzfranskiW , RamirezA , PetersonS . Budesonide/formoterol in single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [Abstract]. In: European Respiratory Society 12th Annual Congress; 2002 Sep 14-18; Stockholm. 2002. ">Szafranski 2003</a>; <a href="./references#CD002991-bbs2-0031" title="TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs2008;68(14):1975-2000. ">Tashkin 2008</a>; <a href="./references#CD002991-bbs2-0033" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819-23. [MEDLINE: 99285938]">Vestbo 1999</a>; <a href="./references#CD002991-bbs2-0034" title="VestboJ , AndersonJA , BrookRD , CalverleyPM , CelliBR , CrimC , et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet2016;387:1817-26. ">Vestbo 2016</a>; <a href="./references#CD002991-bbs2-0035" title="WeirDC , BaleGA , BrightP , Sherwood BurgeP . A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy Supplement1999;29(2):125-8. ">Weir 1999</a>).  </p> </li> </ol> </p> <p>Duration of follow‐up varied between outcomes (see <a href="./full#CD002991-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD002991-sec-0046"> <h5 class="title">Outcomes</h5> <p>The studies measured various outcomes (see <a href="./references#CD002991-sec-0124" title="">Characteristics of included studies</a> table). The long‐term studies (more than six months) reported FEV<sub>1</sub> in terms of rate of decline, and short‐term studies tended to report change in FEV<sub>1</sub> from baseline. Exacerbations were variously reported as dichotomous data (e.g. participants with one or more exacerbations), exacerbation episodes per treatment arm or mean rate per patient per year. Some studies defined exacerbations as changes in healthcare utilisation but mostly as the use of corticosteroid or antibiotic medication or hospitalisation for worsening COPD symptoms. Some studies measured quality of life, symptoms and rescue bronchodilator usage. Long‐term studies also analysed adverse effects. </p> </section> <section id="CD002991-sec-0047"> <h5 class="title">Long‐term studies (longer than six months)</h5> <section id="CD002991-sec-0048"> <h6 class="title">Three‐year studies</h6> <p>There were six large, long‐term trials of ICS versus placebo. All were parallel studies. In the European Respiratory Society Study on COPD (EUROSCOP), Pauwels and colleagues studied 1277 participants treated with BUD 800 µg/day versus placebo for three years (<a href="./references#CD002991-bbs2-0025" title="JohnellO , PauwelsR , Löfdahl C-G, LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. European Respiratory Journal2002;19(6):1058-63. LofdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467-72. PauwelsRA , LofdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of Medicine1999;340(25):1948-53. PauwelsRA , LofdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254-61. ">Pauwels 1999</a>). The participants were current smokers with mild COPD, with mean FEV<sub>1</sub> 77% predicted. </p> <p>The study from Copenhagen reported by Vestbo and colleagues used BUD 1200 µg/day for six months then 800 µg/day for 30 months (total three years) versus placebo in 290 participants (<a href="./references#CD002991-bbs2-0033" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819-23. [MEDLINE: 99285938]">Vestbo 1999</a>). The sample was population‐based and participants were recruited if they had a FEV<sub>1</sub>/vital capacity (VC) ratio of 0.7 or less without bronchodilator reversibility or oral corticosteroid response. Forty percent of participants stated that they had no breathing problems and 4% were never‐smokers. Mean post‐bronchodilator FEV<sub>1</sub> was 86% to 87% predicted.  </p> <p>In the ICS in Obstructive Lung Disease in Europe (ISOLDE) study, Burge and colleagues randomised 751 participants to FP 1000 µg/day versus placebo for three years (<a href="./references#CD002991-bbs2-0003" title="BaleG , Martinez-CamblorP , BurgePS , SorianoJB . Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468-72. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297-303. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654-8. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659-64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW . Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350. D'UrzoAD , CalverleyPM . Withdrawal of treatment in the ISOLDE study [letter]. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161-6. JonesPW , WillitsLR , BurgePS , CalverleyPM . Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68-73. SpencerS , CalverleyPM , BurgePS , JonesPW . Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122-8. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698-702. ">Burge 2000</a>). This was a group of participants with moderate‐to‐severe COPD, with mean FEV<sub>1</sub> 50% of predicted. All were current or ex‐smokers. Most participants received a two‐week oral prednisolone course during the run‐in.  </p> <p>The Lung Health Study (LHS) II enrolled 1116 participants and randomised them to inhaled TAA 1200 µg/day versus placebo for a mean duration of follow‐up of 40 months (<a href="./references#CD002991-bbs2-0019" title="AnthonisenNR , ConnettJC , MurrayRP . Smoking and lung function of Lung Health Study participants after 11 years. American Journal of Respiratory and Critical Care Medicine2002;166(5):675-9. EichenhornMS , WiseRA , MadhokTC , GeraldLB , BaileyWC , TashkinDP , et al. Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest2003;124(1):57-62. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New England Journal of Medicine2000;343(26):1902-9. ScanlonPD , ConnettJE , WiseRA , TashkinDP , MadhokT , SkeansM , et al. Loss of one density with inhaled triamcinolone in Lung Health Study II. American Journal of Respiratory and Critical Care Medicine2004;170(12):1302-9. TashkinDP , MurrayHE , SkeansM , MurrayRP . Skin manifestations of inhaled corticosteroids in COPD patients. Chest2004;126(4):1123-33. ">LHS 2000</a>). Mean FEV<sub>1</sub> was 64% predicted and all were current smokers or ex‐smokers.  </p> <p>The TOwards a Revolution in COPD Health (TORCH) study recruited 6115 participants and randomised them to salmeterol/fluticasone, salmeterol, FP 1000 µg/day (1534 participants) and placebo (1524 participants) (<a href="./references#CD002991-bbs2-0006" title="CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppl 5):A149 [PS-3-8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719-25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775-89. CalverleyPM , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , VestboJ , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD Health (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O-9-2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. San Francisco, California, USA, 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317-22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332-8. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB . Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456-65. FergusonGT , CalverleyPM , AndersonJA . The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. GSK-SCO30003. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.gsk-studyregister.com/en/trial-details/?id=SCO30003#documents-section (first received 7 September 2000). JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research2009;10:59. MehtaRS , KathmanSJ , Daley-YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long-term twice-daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:Poster #A41. The TORCH study group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206-10. ">Calverley 2007</a>). </p> <p>The COOPT trial recruited 286 participants (78% with COPD, 22% with chronic bronchitis) from 44 general practices and randomised them to FP 500 µg twice daily or placebo for three years (N‐acetylcysteine was used in a separate arm) (<a href="./references#CD002991-bbs2-0027" title="ChavannesNH , SchermerTR , WoutersEF , AkkermansRP , DekhuijzenRP , MurisJW , et al. Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International Journal of COPD2009;4:431-6. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103(4):542-51. ">Schermer 2009</a>). </p> </section> <section id="CD002991-sec-0049"> <h6 class="title">Two‐year studies</h6> <p>There were five parallel studies of two years' duration in people with COPD (<a href="./references#CD002991-bbs2-0008" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. ">Derenne 1995</a>; <a href="./references#CD002991-bbs2-0017" title="LapperreTS , Snoeck-StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517-27. ">Lapperre 2009</a>; <a href="./references#CD002991-bbs2-0026" title="RenkemaTE , SchoutenJP , KoeterGH , PostmaDS . Effects of long-term treatment with corticosteroids in COPD. Chest1996;109(5):1156-62. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. ">Renkema 1996</a>; <a href="./references#CD002991-bbs2-0034" title="VestboJ , AndersonJA , BrookRD , CalverleyPM , CelliBR , CrimC , et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet2016;387:1817-26. ">Vestbo 2016</a>; <a href="./references#CD002991-bbs2-0035" title="WeirDC , BaleGA , BrightP , Sherwood BurgeP . A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy Supplement1999;29(2):125-8. ">Weir 1999</a>). <a href="./references#CD002991-bbs2-0008" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. ">Derenne 1995</a> was reported in abstract form and summarised in the meta‐analysis by van Grunsven and colleagues (<a href="./references#CD002991-bbs2-0133" title="vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. [DOI: 10.1136/thx.54.1.7]">van Grunsven 1999</a>). <a href="./references#CD002991-bbs2-0026" title="RenkemaTE , SchoutenJP , KoeterGH , PostmaDS . Effects of long-term treatment with corticosteroids in COPD. Chest1996;109(5):1156-62. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. ">Renkema 1996</a> studied 39 participants treated with BUD 1500 µg/day versus placebo for two years. <a href="./references#CD002991-bbs2-0035" title="WeirDC , BaleGA , BrightP , Sherwood BurgeP . A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy Supplement1999;29(2):125-8. ">Weir 1999</a> studied 98 participants treated with BDP 1500 µg/day versus placebo for two years. The meta‐analysis by van Grunsven and colleagues combined the data from the COPD subgroups of <a href="./references#CD002991-bbs2-0015" title="KapteinAA , BrandPL , DekkerFW , KerstjensHA , PostmaDS , SluiterHJ . Quality-of-life in a long-term multicentre trial in chronic nonspecific lung disease: assessment at baseline. The Dutch CNSLD Study Group. European Respiratory Journal1993;6(10):1479-84. KerstjensHA , BrandPL , HughesMD , RobinsonNJ , PostmaDS , SluiterHJ , et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. New England Journal of Medicine1992;327(20):1413-9. KerstjensHA , BrandPL , QuanjerPH , van derBruggen-BogaartsBA , KoeterGH , et al. Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group. Thorax1993;48(7):722-9. KerstjensHA , BrandPL , deJongPM , KoeterGH , PostmaDS . Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group. Thorax1994;49(11):1109-15. KerstjensHA , OverbeekSE , SchoutenJP , BrandPL , PostmaDS . Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. European Respiratory Journal1993;6(6):868-76. KerstjensHA , PostmaDS , vanDoormaalJJ , vanZantenAK , BrandPL , DekhuijzenPN , et al. Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group. Thorax1994;49(7):652-6. KerstjensHA , SchoutenJP , BrandPL , SchoonbroodDF , SterkPJ , PostmaDS . Importance of total serum IgE for improvement in airways hyperresponsiveness with inhaled corticosteroids in asthma and chronic obstructive pulmonary disease. The Dutch CNSLD Study Group. American Journal of Respiratory and Critical Care Medicine1995;151(2 Pt 1):360-8. OverbeekSE , KerstjensHA , BogaardJM , MulderPG , PostmaDS . Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? The Dutch CNSLD Study Group. The Dutch Chronic Nonspecific Lung Disease Study Groups. Chest1996;110(1):35-41. Rutten-van MolkenMP , vanDoorslaerEK , JansenMC , KerstjensHA , RuttenFF . Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1995;151(4):975-82. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. ">Kerstjens 1992</a>, which included people with COPD with BHR, <a href="./references#CD002991-bbs2-0008" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. ">Derenne 1995</a>, and <a href="./references#CD002991-bbs2-0026" title="RenkemaTE , SchoutenJP , KoeterGH , PostmaDS . Effects of long-term treatment with corticosteroids in COPD. Chest1996;109(5):1156-62. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. ">Renkema 1996</a> (<a href="./references#CD002991-bbs2-0133" title="vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. [DOI: 10.1136/thx.54.1.7]">van Grunsven 1999</a>) (see <a href="#CD002991-sec-0090">Discussion</a> for details). <a href="./references#CD002991-bbs2-0017" title="LapperreTS , Snoeck-StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517-27. ">Lapperre 2009</a> randomised 114 participants with moderate‐to‐severe COPD to FP 500 µg twice daily for six or 30 months, or placebo twice daily (salmeterol/fluticasone was used in a separate arm). One trial of two to four years' duration studied the effect of BUD 800 µg daily on lung density in people with COPD (<a href="./references#CD002991-bbs2-0029" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , MaltbaekN , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD2009;6(2):104-11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD2011;8(1):2-7. ">Shaker 2009</a>).  </p> <p>The Study to Understand Mortality and Morbidity in COPD (SUMMIT) by Vestbo and colleagues randomised 16,590 participants to receive combination fluticasone/vilanterol, vilanterol 100 µg/day, FF (4135 participants) or placebo (4111 participants) (<a href="./references#CD002991-bbs2-0034" title="VestboJ , AndersonJA , BrookRD , CalverleyPM , CelliBR , CrimC , et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet2016;387:1817-26. ">Vestbo 2016</a>). This was an event‐driven study with a median study duration of 1.8 years. Participants had moderate COPD (FEV<sub>1</sub> 50% to 70% predicted) and either an increased risk of or established cardiovascular disease. </p> </section> <section id="CD002991-sec-0050"> <h6 class="title">One‐year studies</h6> <p>Four parallel studies of combined ICS/LABA in people with COPD included ICS versus placebo arms. In the one‐year TRISTAN study of salmeterol/FP, salmeterol, FP or placebo by Calverley and colleagues in 1465 participants, data were available for FP 1000 µg/day versus placebo in one of the comparisons (<a href="./references#CD002991-bbs2-0004" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449-56. CalverleyPM , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. www.abstracts2view.com (accessed prior to 11 March 2022). CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). GSK-SFCB3024. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. www.gsk-studyregister.com/en/trial-details/?id=SFCB3024 (first received 1 August 1998). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004:D22 Poster 503. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference [A39] [Poster K39]. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPM , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003:P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist2004;45(6):727-8. PauwelsRA , CalverlyPM , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1569]. PauwelsRA , VestboJ , CalverleyPM , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619-37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPM , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301-4. VestboJ , PauwelsRA , CalverleyPM , JonesPW , PrideNB , GulsvikA . Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045-50. ">Calverley 2003a</a>). Szafranski and colleagues studied BUD/formoterol, BUD, formoterol or placebo in 812 participants with COPD for one year (<a href="./references#CD002991-bbs2-0030" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii43. CalverleyPM , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverleyPM . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57 (Suppl 3):S145. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. In: BTS Winter Meeting, 2002 Dec 4-6; London. 2002:S143. CampbellLW , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate-severe COPD. In: BTS Winter Meeting, 2002 Dec 4-6; London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night-time awakenings in moderate-severe COPD: results from symptoms and night-time awakenings in moderate to severe COPD: results from a 1-year study. European Respiratory Journal2002;20(Suppl 38):242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004:D22 Poster 525. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20(Suppl 38):250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1-year study of patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20(Suppl 38):242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14-21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21:74-81. SzfranskiW , RamirezA , PetersonS . Budesonide/formoterol in single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [Abstract]. In: European Respiratory Society 12th Annual Congress; 2002 Sep 14-18; Stockholm. 2002. ">Szafranski 2003</a>). Calverley and colleagues similarly studied BUD/formoterol, BUD, formoterol or placebo in 1022 participants with COPD for one year (<a href="./references#CD002991-bbs2-0005" title="BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912-9. CalverleyPM , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P436. CalverleyPM , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. CalverleyPM , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:B024 Poster 418. CalverleyPM , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:D092 Poster 211. CalverleyPM , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. In: American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego. 2005. CalverleyPM , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. In: American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando. 2004. HalpinDMG , LarssonT , CalverleyPM . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. In: American Thoracic Society 2005 International Conference; May 20-25; San Diego. 2005. JonesPW , StåhlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [Abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health-related quality of life in patients with COPD. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365-75. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14-21. ">Calverley 2003b</a>). One unpublished study of salmeterol/FP in COPD included a comparison of FP 1000 µg/day versus placebo in 256 participants with COPD (<a href="./references#CD002991-bbs2-0011" title="GSK-SCO30002. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. www.gsk-studyregister.com/en/trial-details/?id=SCO30002 (first received 11 January 2006). ">GSK‐SCO30002</a>). </p> <p>Calverley and colleagues randomised 911 participants with moderate‐to‐severe COPD to MF‐DPI 800 µg once daily, MF‐DPI 400 µg twice daily or placebo (<a href="./references#CD002991-bbs2-0007" title="CalverleyP , PauwelsR , NieminemM , StryszakP , StaudingerH , LeeT . Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003:P155. CalverleyPM , RennardS , NelsonHS , KarpelJP , AbbateEH , StryszakP , et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respiratory Research2008;9:73. [1465-993X: (Electronic)] NelsonH , KarpelJP , StaudingerH , BusseWW . Mometasone furoate dry powder inhaler (MF-DPI) improves FEV1, symptoms, quality of life and reduces exacerbations in patients with COPD. Chest2004;236(4 Suppl):709s-10s. ">Calverley 2008</a>). </p> </section> <section id="CD002991-sec-0051"> <h6 class="title">Three‐month studies</h6> <section id="CD002991-sec-0052"> <p><b>Parallel studies</b></p> <p><a href="./references#CD002991-bbs2-0022" title="MiriciA , BektasY , OzbakisG , ErmanZ . Effect of inhaled corticosteroids on respiratory function tests and airway inflammation in stable chronic obstructive pulmonary disease. Clinical Drug Investigation2001;21(12):835-42. ">Mirici 2001</a> studied 40 participants with COPD using BUD 800 µg/day versus placebo for 12 weeks. <a href="./references#CD002991-bbs2-0013" title="GizyckiMJ , HattotuwaKL , BarnesN , JefferyPK . Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax2002;57(9):799-803. HattotuwaKL , GizyckiMJ , AnsariTW , JefferyPK , BarnesNC . The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;165(12):1592-9. ">Hattotuwa 2002</a> randomised 31 participants to FP 1000 µg/day versus placebo for three months in a biopsy study. <a href="./references#CD002991-bbs2-0036" title="YildizF , BasyigitI , YildirimE , BoyaciH , IlgazliA . Does addition of inhaled steroids to combined bronchodilator therapy affect health status in patients with COPD?Respirology2004;9(3):352-5. ">Yildiz 2004</a> studied 38 participants with COPD using BUD 800 µg/day versus placebo. In a biopsy study, <a href="./references#CD002991-bbs2-0002" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007;62(11):938-43. ">Bourbeau 2007</a> randomised 60 participants to salmeterol/FP twice daily, FP 500 µg twice daily or placebo. One unpublished study randomised 217 participants from multiple centres to placebo tablets (two weeks) followed by FP 500 µg twice daily (12 weeks), or prednisolone 20 mg to 40 mg daily plus placebo inhaler (two weeks) followed by FP 500 µg twice daily (10 weeks), or placebo tablets (two weeks) followed by placebo inhaler (12 weeks) (<a href="./references#CD002991-bbs2-0009" title="FCO30002. A multicentre, randomised, placebo-controlled, double-blind comparison with 3 parallel groups to investigate the efficacy and safety of inhaled glucocorticoid fluticasone (500 μg bd via Diskus™) vs. oral glucocorticoid therapy vs. placebo in subjects with chronic obstructive airway disease (COPD) under therapy with salmeterol (50 μg bd). GlaxoSmithKline Clinical Trial Register2005. ">GSK FCO30002</a>). </p> </section> <section id="CD002991-sec-0053"> <p><b>Crossover studies</b></p> <p><a href="./references#CD002991-bbs2-0014" title="JohnM , BosseS , OltmannsU , SchumacherA , WittC . Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respiratory Medicine2005;99(11):1418-24. JohnM , BosseS , SchumacherA , OltmannsU , WittC . Effects of inhaled beclomethasone HFA 134 (qvar/ventoiair) on health related quality of life in patients with chronic obstructive pulmonary disease [Abstract]. In: American Thoracic Society International Conference; 2005 May 20-25; San Diego. 2005:Poster A43. ">John 2005</a> performed a cross‐over study of 11 participants using HFA‐BDP 800 µg/day versus placebo. </p> </section> </section> <section id="CD002991-sec-0054"> <h6 class="title">Six‐month studies</h6> <section id="CD002991-sec-0055"> <p><b>Parallel studies</b></p> <p><a href="./references#CD002991-bbs2-0001" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477-82. ">Bourbeau 1998</a> used BUD 1600 µg/day versus placebo in 79 participants with COPD who were non‐responders to oral corticosteroids. <a href="./references#CD002991-bbs2-0024" title="FLIT97. A multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000µg daily with placebo in chronic obstructive pulmonary disease. ctr.gsk.co.uk2005. PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773-80. ">Paggiaro 1998</a> studied 281 participants treated with FP 1000 µg/day versus placebo. <a href="./references#CD002991-bbs2-0028" title="SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respiratory Medicine1999;93(10):715-8. ">Senderovitz 1999</a> studied 40 participants treated with BUD 800 µg/day versus placebo. In a study published in abstract form, <a href="./references#CD002991-bbs2-0018" title="LaptsevaIM , LaptsevaEA , BorshchevskyVV , GurevichG , KalechitsO . Inhaled budesonide in the management of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):244s. ">Laptseva 2002</a> treated 49 participants with BUD 800 µg/day versus placebo. <a href="./references#CD002991-bbs2-0020" title="GSK SFCA3006. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3006 (first accessed 24 September 1998). MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). www.abstracts2view.com (accessed prior to 9 September 2022). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084-91. ">Mahler 2002</a> studied 691 participants treated with FP 1000 µg/day or placebo for 24 weeks. Hanania and colleagues, in a similar study design, used half the FP dose (500 µg/day) (<a href="./references#CD002991-bbs2-0012" title="GSK SFCA3007. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3007 (first received 10 November 1998). HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834-43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine2001;163(Suppl 5):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22(Suppl 45):P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. In: US COPD Coalition National COPD Conference 2003; Nov 14-15, Arlington. 2003:1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P429. ">GSK SFCA3007</a>).  </p> <p><a href="./references#CD002991-bbs2-0023" title="OzolD , AysanT , SolakZA , MogulkocN , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respiratory Medicine2005;99(12):1494-500. ">Ozol 2005</a>, a biomarker study, treated 26 participants with BUD 800 µg/day versus placebo. An unpublished study treated 640 participants with FP 500 µg twice daily versus placebo (<a href="./references#CD002991-bbs2-0010" title="FLTA3025. A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250mcg BID, 500mcg BID, and placebo BID via the DISKUS in subjects with chronic obstructive pulmonary disease (COPD). www.gsk-studyregister.com/en/trial-details/?id=FLTA3025 (first received 8 August 1998). ">GSK FLTA3025</a>). <a href="./references#CD002991-bbs2-0031" title="TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs2008;68(14):1975-2000. ">Tashkin 2008</a> studied BUD 640 µg/day versus placebo for six months.  </p> <p><a href="./references#CD002991-bbs2-0032" title="TashkinDP , DohertyDE , KerwinE , Matiz-BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73-86. ">Tashkin 2012</a> randomised 2251 participants with moderate‐to‐very severe COPD (post‐bronchodilator FEV<sub>1</sub> 25% to 60% predicted) to 26 weeks of MF/formoterol fumarate, formoterol fumarate, MF 800 µg/day (463 participants) or placebo (448 participants). <a href="./references#CD002991-bbs2-0016" title="KerwinEM , Scott-WilsonC , SanfordL , RennardS , AgustiA , BarnesN , et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respiratory Medicine2013;107:560-9. ">Kerwin 2013</a> randomised 1030 participants with moderate‐to‐severe COPD to combination FF/vilanterol, vilanterol, FF 100 µg/day (206 participants) or placebo (207 participants). <a href="./references#CD002991-bbs2-0021" title="MartinezFJ , BosciaJ , FeldmanG , Scott-WilsonC , KilbrideS , FabbriL , et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respiratory Medicine2013;107:550-9. ">Martinez 2013</a> randomised 1224 participants to FF/vilanterol, vilanterol, FF 100 µg/day (204 participants), FF 200 µg/day (203 participants) or placebo (205 participants).  </p> </section> </section> </section> </section> <section id="CD002991-sec-0056"> <h4 class="title">Excluded studies</h4> <p>We excluded 71 studies after full‐text review, with reasons for exclusion given in the <a href="./references#CD002991-sec-0125" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD002991-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>The quality of published studies was generally good, although many studies had unclear risk of bias in relation to randomisation method and allocation concealment. Unpublished abstracts generally had greater risk of bias, due to lack of details in reporting. See <a href="#CD002991-fig-0002">Figure 2</a>. In total, 14 studies had a low risk of bias with 18 studies recording a combination of low and unclear risk of bias. Two studies recorded a high risk of attrition bias (<a href="./references#CD002991-bbs2-0001" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477-82. ">Bourbeau 1998</a>; <a href="./references#CD002991-bbs2-0015" title="KapteinAA , BrandPL , DekkerFW , KerstjensHA , PostmaDS , SluiterHJ . Quality-of-life in a long-term multicentre trial in chronic nonspecific lung disease: assessment at baseline. The Dutch CNSLD Study Group. European Respiratory Journal1993;6(10):1479-84. KerstjensHA , BrandPL , HughesMD , RobinsonNJ , PostmaDS , SluiterHJ , et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. New England Journal of Medicine1992;327(20):1413-9. KerstjensHA , BrandPL , QuanjerPH , van derBruggen-BogaartsBA , KoeterGH , et al. Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group. Thorax1993;48(7):722-9. KerstjensHA , BrandPL , deJongPM , KoeterGH , PostmaDS . Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group. Thorax1994;49(11):1109-15. KerstjensHA , OverbeekSE , SchoutenJP , BrandPL , PostmaDS . Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. European Respiratory Journal1993;6(6):868-76. KerstjensHA , PostmaDS , vanDoormaalJJ , vanZantenAK , BrandPL , DekhuijzenPN , et al. Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group. Thorax1994;49(7):652-6. KerstjensHA , SchoutenJP , BrandPL , SchoonbroodDF , SterkPJ , PostmaDS . Importance of total serum IgE for improvement in airways hyperresponsiveness with inhaled corticosteroids in asthma and chronic obstructive pulmonary disease. The Dutch CNSLD Study Group. American Journal of Respiratory and Critical Care Medicine1995;151(2 Pt 1):360-8. OverbeekSE , KerstjensHA , BogaardJM , MulderPG , PostmaDS . Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? The Dutch CNSLD Study Group. The Dutch Chronic Nonspecific Lung Disease Study Groups. Chest1996;110(1):35-41. Rutten-van MolkenMP , vanDoorslaerEK , JansenMC , KerstjensHA , RuttenFF . Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1995;151(4):975-82. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. ">Kerstjens 1992</a>).  </p> <div class="figure" id="CD002991-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002991-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD002991-sec-0058"> <h4 class="title">Allocation</h4> <p>Studies used random allocation. However, many studies did not specifically state the randomisation method, or whether allocation was concealed. </p> </section> <section id="CD002991-sec-0059"> <h4 class="title">Blinding</h4> <p>All published studies were double‐blind. Several studies presented in abstract form did not specifically state whether the study was double‐blind. </p> </section> <section id="CD002991-sec-0060"> <h4 class="title">Incomplete outcome data</h4> <p>The attrition rate was acceptable in most studies. Studies with higher attrition rates provided adequate detail about the rates of withdrawal in the ICS and placebo arms. </p> </section> <section id="CD002991-sec-0061"> <h4 class="title">Selective reporting</h4> <p>Some studies had published a trial protocol prior to the main manuscript and had been listed on a trials registry database. </p> </section> <section id="CD002991-sec-0062"> <h4 class="title">Other potential sources of bias</h4> <p>Most studies were industry‐funded.</p> </section> </section> <section id="CD002991-sec-0063"> <h3 class="title" id="CD002991-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD002991-tbl-0001"><b>Summary of findings 1</b> Summary of findings table ‐ ICS compared to placebo for adults with stable chronic obstructive pulmonary disease in studies of greater than six months? duration</a> </p> <p>We analysed data in two comparisons based on study duration (three‐ to six‐month studies or longer than six‐month studies). These comparisons were further split based on ICS dosage (equivalent beclomethasone dosage to indicate high (1000 µg or greater) or low ICS (less than 1000 µg) dosage subgroups). </p> <section id="CD002991-sec-0064"> <h4 class="title">Long‐term studies (longer than six months)</h4> <section id="CD002991-sec-0065"> <h5 class="title">Exacerbations of chronic obstructive pulmonary disease</h5> <p>Using the generic inverse variance function, pooling was possible for five long‐term studies (<a href="./references#CD002991-bbs2-0003" title="BaleG , Martinez-CamblorP , BurgePS , SorianoJB . Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468-72. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297-303. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654-8. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659-64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW . Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350. D'UrzoAD , CalverleyPM . Withdrawal of treatment in the ISOLDE study [letter]. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161-6. JonesPW , WillitsLR , BurgePS , CalverleyPM . Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68-73. SpencerS , CalverleyPM , BurgePS , JonesPW . Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122-8. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698-702. ">Burge 2000</a>; <a href="./references#CD002991-bbs2-0004" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449-56. CalverleyPM , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. www.abstracts2view.com (accessed prior to 11 March 2022). CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). GSK-SFCB3024. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. www.gsk-studyregister.com/en/trial-details/?id=SFCB3024 (first received 1 August 1998). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004:D22 Poster 503. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference [A39] [Poster K39]. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPM , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003:P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist2004;45(6):727-8. PauwelsRA , CalverlyPM , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1569]. PauwelsRA , VestboJ , CalverleyPM , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619-37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPM , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301-4. VestboJ , PauwelsRA , CalverleyPM , JonesPW , PrideNB , GulsvikA . Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045-50. ">Calverley 2003a</a>; <a href="./references#CD002991-bbs2-0005" title="BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912-9. CalverleyPM , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P436. CalverleyPM , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. CalverleyPM , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:B024 Poster 418. CalverleyPM , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:D092 Poster 211. CalverleyPM , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. In: American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego. 2005. CalverleyPM , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. In: American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando. 2004. HalpinDMG , LarssonT , CalverleyPM . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. In: American Thoracic Society 2005 International Conference; May 20-25; San Diego. 2005. JonesPW , StåhlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [Abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health-related quality of life in patients with COPD. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365-75. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14-21. ">Calverley 2003b</a>; <a href="./references#CD002991-bbs2-0030" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii43. CalverleyPM , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverleyPM . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57 (Suppl 3):S145. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. In: BTS Winter Meeting, 2002 Dec 4-6; London. 2002:S143. CampbellLW , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate-severe COPD. In: BTS Winter Meeting, 2002 Dec 4-6; London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night-time awakenings in moderate-severe COPD: results from symptoms and night-time awakenings in moderate to severe COPD: results from a 1-year study. European Respiratory Journal2002;20(Suppl 38):242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004:D22 Poster 525. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20(Suppl 38):250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1-year study of patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20(Suppl 38):242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14-21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21:74-81. SzfranskiW , RamirezA , PetersonS . Budesonide/formoterol in single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [Abstract]. In: European Respiratory Society 12th Annual Congress; 2002 Sep 14-18; Stockholm. 2002. ">Szafranski 2003</a>; <a href="./references#CD002991-bbs2-0034" title="VestboJ , AndersonJA , BrookRD , CalverleyPM , CelliBR , CrimC , et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet2016;387:1817-26. ">Vestbo 2016</a>), and the meta‐analysis of three long‐term studies (<a href="./references#CD002991-bbs2-0133" title="vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. [DOI: 10.1136/thx.54.1.7]">van Grunsven 1999</a>). The rate ratio for this analysis was 0.88 exacerbations per participant per year with ICS (95% CI 0.82 to 0.94; I<sup>2</sup> = 48%; 5 studies; 10,097 participants; moderate‐certainty evidence; <a href="./references#CD002991-fig-0009" title="">Analysis 1.2</a>; <a href="#CD002991-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD002991-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Figure 3: Forest plot (1.2 Exacerbation rate (mean difference))." data-id="CD002991-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Figure 3: Forest plot (1.2 Exacerbation rate (mean difference)).</p> </div> </div> </div> <p>We also pooled mean rate of exacerbation per participant per year using data from treatment and control groups from five long‐term studies (<a href="./references#CD002991-bbs2-0003" title="BaleG , Martinez-CamblorP , BurgePS , SorianoJB . Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468-72. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297-303. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654-8. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659-64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW . Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350. D'UrzoAD , CalverleyPM . Withdrawal of treatment in the ISOLDE study [letter]. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161-6. JonesPW , WillitsLR , BurgePS , CalverleyPM . Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68-73. SpencerS , CalverleyPM , BurgePS , JonesPW . Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122-8. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698-702. ">Burge 2000</a>; <a href="./references#CD002991-bbs2-0004" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449-56. CalverleyPM , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. www.abstracts2view.com (accessed prior to 11 March 2022). CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). GSK-SFCB3024. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. www.gsk-studyregister.com/en/trial-details/?id=SFCB3024 (first received 1 August 1998). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004:D22 Poster 503. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference [A39] [Poster K39]. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPM , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003:P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist2004;45(6):727-8. PauwelsRA , CalverlyPM , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1569]. PauwelsRA , VestboJ , CalverleyPM , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619-37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPM , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301-4. VestboJ , PauwelsRA , CalverleyPM , JonesPW , PrideNB , GulsvikA . Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045-50. ">Calverley 2003a</a>; <a href="./references#CD002991-bbs2-0030" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii43. CalverleyPM , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverleyPM . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57 (Suppl 3):S145. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. In: BTS Winter Meeting, 2002 Dec 4-6; London. 2002:S143. CampbellLW , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate-severe COPD. In: BTS Winter Meeting, 2002 Dec 4-6; London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night-time awakenings in moderate-severe COPD: results from symptoms and night-time awakenings in moderate to severe COPD: results from a 1-year study. European Respiratory Journal2002;20(Suppl 38):242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004:D22 Poster 525. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20(Suppl 38):250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1-year study of patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20(Suppl 38):242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14-21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21:74-81. SzfranskiW , RamirezA , PetersonS . Budesonide/formoterol in single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [Abstract]. In: European Respiratory Society 12th Annual Congress; 2002 Sep 14-18; Stockholm. 2002. ">Szafranski 2003</a>; <a href="./references#CD002991-bbs2-0027" title="ChavannesNH , SchermerTR , WoutersEF , AkkermansRP , DekhuijzenRP , MurisJW , et al. Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International Journal of COPD2009;4:431-6. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103(4):542-51. ">Schermer 2009</a>; <a href="./references#CD002991-bbs2-0034" title="VestboJ , AndersonJA , BrookRD , CalverleyPM , CelliBR , CrimC , et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet2016;387:1817-26. ">Vestbo 2016</a>), and a combined rate from the <a href="./references#CD002991-bbs2-0133" title="vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. [DOI: 10.1136/thx.54.1.7]">van Grunsven 1999</a> meta‐analysis of three long‐term studies. The MD was −0.05 exacerbations per participant per year with ICS (95% CI −0.07 to −0.02; I<sup>2</sup> = 78%; 5 studies, 10,316 participants; moderate‐certainty evidence; <a href="./references#CD002991-fig-0008" title="">Analysis 1.1</a>; <a href="#CD002991-fig-0004">Figure 4</a>). The SUMMIT study was the main contributor to this analysis result with a lower exacerbation rate of 0.31 in the ICS group compared to 0.35 in the placebo (P = 0.004; <a href="./references#CD002991-bbs2-0034" title="VestboJ , AndersonJA , BrookRD , CalverleyPM , CelliBR , CrimC , et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet2016;387:1817-26. ">Vestbo 2016</a>).  </p> <div class="figure" id="CD002991-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Figure 3: Forest plot (1.2 Exacerbation rate)." data-id="CD002991-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Figure 3: Forest plot (1.2 Exacerbation rate).</p> </div> </div> </div> <p>Other long‐term studies did not report exacerbation events in sufficient detail for pooling as a mean rate of exacerbation per participant per year. The results of these studies were: no difference in mean exacerbation rates per year between BDP (0.36/year) and placebo (0.57/year) (<a href="./references#CD002991-bbs2-0035" title="WeirDC , BaleGA , BrightP , Sherwood BurgeP . A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy Supplement1999;29(2):125-8. ">Weir 1999</a>), no difference in total number of exacerbations between BUD (155 exacerbations) and placebo (161 exacerbations) (<a href="./references#CD002991-bbs2-0033" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819-23. [MEDLINE: 99285938]">Vestbo 1999</a>), and reduced number of unscheduled physician visits and hospitalisation for respiratory conditions (data not stated) (<a href="./references#CD002991-bbs2-0019" title="AnthonisenNR , ConnettJC , MurrayRP . Smoking and lung function of Lung Health Study participants after 11 years. American Journal of Respiratory and Critical Care Medicine2002;166(5):675-9. EichenhornMS , WiseRA , MadhokTC , GeraldLB , BaileyWC , TashkinDP , et al. Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest2003;124(1):57-62. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New England Journal of Medicine2000;343(26):1902-9. ScanlonPD , ConnettJE , WiseRA , TashkinDP , MadhokT , SkeansM , et al. Loss of one density with inhaled triamcinolone in Lung Health Study II. American Journal of Respiratory and Critical Care Medicine2004;170(12):1302-9. TashkinDP , MurrayHE , SkeansM , MurrayRP . Skin manifestations of inhaled corticosteroids in COPD patients. Chest2004;126(4):1123-33. ">LHS 2000</a>). One unpublished study reported the total number of exacerbations without performing an analysis, with 123 exacerbations in the FP group and 127 exacerbations in the placebo group (<a href="./references#CD002991-bbs2-0011" title="GSK-SCO30002. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. www.gsk-studyregister.com/en/trial-details/?id=SCO30002 (first received 11 January 2006). ">GSK‐SCO30002</a>). In the TORCH study, the mean number of exacerbations per year was 0.93 in the FP group compared to 1.13 in the placebo group, giving a rate ratio of 0.82 (95% CI 0.76 to 0.89, P &lt; 0.001) (<a href="./references#CD002991-bbs2-0006" title="CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppl 5):A149 [PS-3-8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719-25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775-89. CalverleyPM , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , VestboJ , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD Health (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O-9-2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. San Francisco, California, USA, 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317-22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332-8. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB . Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456-65. FergusonGT , CalverleyPM , AndersonJA . The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. GSK-SCO30003. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.gsk-studyregister.com/en/trial-details/?id=SCO30003#documents-section (first received 7 September 2000). JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research2009;10:59. MehtaRS , KathmanSJ , Daley-YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long-term twice-daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:Poster #A41. The TORCH study group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206-10. ">Calverley 2007</a>). The EUROSCOP study did not report exacerbation rates (<a href="./references#CD002991-bbs2-0025" title="JohnellO , PauwelsR , Löfdahl C-G, LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. European Respiratory Journal2002;19(6):1058-63. LofdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467-72. PauwelsRA , LofdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of Medicine1999;340(25):1948-53. PauwelsRA , LofdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254-61. ">Pauwels 1999</a>). </p> <p>Three studies reported percentage of participants with at least one exacerbation (<a href="./references#CD002991-fig-0010" title="">Analysis 1.3</a>). Pooling of these results showed an OR of 0.89 (95% CI 0.72 to 1.12; 1421 participants). </p> </section> <section id="CD002991-sec-0066"> <h5 class="title">Quality of life </h5> <p>We pooled the data of five long‐term studies for rate of change in St George's Respiratory Questionnaire (SGRQ) in units/year using the generic inverse variance function (<a href="./references#CD002991-bbs2-0003" title="BaleG , Martinez-CamblorP , BurgePS , SorianoJB . Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468-72. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297-303. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654-8. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659-64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW . Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350. D'UrzoAD , CalverleyPM . Withdrawal of treatment in the ISOLDE study [letter]. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161-6. JonesPW , WillitsLR , BurgePS , CalverleyPM . Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68-73. SpencerS , CalverleyPM , BurgePS , JonesPW . Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122-8. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698-702. ">Burge 2000</a>; <a href="./references#CD002991-bbs2-0004" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449-56. CalverleyPM , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. www.abstracts2view.com (accessed prior to 11 March 2022). CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). GSK-SFCB3024. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. www.gsk-studyregister.com/en/trial-details/?id=SFCB3024 (first received 1 August 1998). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004:D22 Poster 503. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference [A39] [Poster K39]. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPM , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003:P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist2004;45(6):727-8. PauwelsRA , CalverlyPM , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1569]. PauwelsRA , VestboJ , CalverleyPM , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619-37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPM , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301-4. VestboJ , PauwelsRA , CalverleyPM , JonesPW , PrideNB , GulsvikA . Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045-50. ">Calverley 2003a</a>; <a href="./references#CD002991-bbs2-0005" title="BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912-9. CalverleyPM , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P436. CalverleyPM , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. CalverleyPM , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:B024 Poster 418. CalverleyPM , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:D092 Poster 211. CalverleyPM , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. In: American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego. 2005. CalverleyPM , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. In: American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando. 2004. HalpinDMG , LarssonT , CalverleyPM . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. In: American Thoracic Society 2005 International Conference; May 20-25; San Diego. 2005. JonesPW , StåhlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [Abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health-related quality of life in patients with COPD. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365-75. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14-21. ">Calverley 2003b</a>; <a href="./references#CD002991-bbs2-0011" title="GSK-SCO30002. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. www.gsk-studyregister.com/en/trial-details/?id=SCO30002 (first received 11 January 2006). ">GSK‐SCO30002</a>; <a href="./references#CD002991-bbs2-0030" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii43. CalverleyPM , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverleyPM . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57 (Suppl 3):S145. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. In: BTS Winter Meeting, 2002 Dec 4-6; London. 2002:S143. CampbellLW , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate-severe COPD. In: BTS Winter Meeting, 2002 Dec 4-6; London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night-time awakenings in moderate-severe COPD: results from symptoms and night-time awakenings in moderate to severe COPD: results from a 1-year study. European Respiratory Journal2002;20(Suppl 38):242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004:D22 Poster 525. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20(Suppl 38):250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1-year study of patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20(Suppl 38):242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14-21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20(Suppl 38):242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21:74-81. SzfranskiW , RamirezA , PetersonS . Budesonide/formoterol in single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [Abstract]. In: European Respiratory Society 12th Annual Congress; 2002 Sep 14-18; Stockholm. 2002. ">Szafranski 2003</a>). There was a slowing in the rate of decline of quality of life in the ICS group compared to placebo (MD −1.22 units/year, 95% CI −1.83 to −0.60; I<sup>2</sup> = 0%; 5 studies; 2507 participants; moderate‐certainty evidence; minimal clinically important difference (MCID) 4 points; <a href="./references#CD002991-fig-0013" title="">Analysis 1.6</a>). There was no improvement in quality of life with ICS using the 36‐item Short Form (SF‐36) (<a href="./references#CD002991-bbs2-0019" title="AnthonisenNR , ConnettJC , MurrayRP . Smoking and lung function of Lung Health Study participants after 11 years. American Journal of Respiratory and Critical Care Medicine2002;166(5):675-9. EichenhornMS , WiseRA , MadhokTC , GeraldLB , BaileyWC , TashkinDP , et al. Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest2003;124(1):57-62. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New England Journal of Medicine2000;343(26):1902-9. ScanlonPD , ConnettJE , WiseRA , TashkinDP , MadhokT , SkeansM , et al. Loss of one density with inhaled triamcinolone in Lung Health Study II. American Journal of Respiratory and Critical Care Medicine2004;170(12):1302-9. TashkinDP , MurrayHE , SkeansM , MurrayRP . Skin manifestations of inhaled corticosteroids in COPD patients. Chest2004;126(4):1123-33. ">LHS 2000</a>). The TORCH study reported a mean benefit in SGRQ of −2.0 units averaged over three years (95% CI −2.9 to −1.0) with FP compared to placebo (<a href="./references#CD002991-bbs2-0006" title="CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppl 5):A149 [PS-3-8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719-25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775-89. CalverleyPM , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , VestboJ , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD Health (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O-9-2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. San Francisco, California, USA, 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317-22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332-8. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB . Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456-65. FergusonGT , CalverleyPM , AndersonJA . The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. GSK-SCO30003. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.gsk-studyregister.com/en/trial-details/?id=SCO30003#documents-section (first received 7 September 2000). JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research2009;10:59. MehtaRS , KathmanSJ , Daley-YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long-term twice-daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:Poster #A41. The TORCH study group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206-10. ">Calverley 2007</a>). </p> </section> <section id="CD002991-sec-0067"> <h5 class="title">Lung function</h5> <p>In the studies of greater than six months' duration, we analysed the main treatment effect of change in rate of FEV<sub>1</sub> decline. We used two approaches to analysing rate of decline of postbronchodilator FEV<sub>1</sub> due to the various ways the studies presented data. </p> <p>When analysing data using generic inverse variance, the pooled difference in rate of decline in postbronchodilator FEV<sub>1</sub> in five studies was 6.31 mL/year (95% CI 1.76 to 10.85; I<sup>2</sup> = 0%; 9829 participants; moderate‐certainty evidence; <a href="./references#CD002991-fig-0015" title="">Analysis 1.8</a>; <a href="#CD002991-fig-0005">Figure 5</a>) (<a href="./references#CD002991-bbs2-0003" title="BaleG , Martinez-CamblorP , BurgePS , SorianoJB . Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468-72. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297-303. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654-8. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659-64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW . Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350. D'UrzoAD , CalverleyPM . Withdrawal of treatment in the ISOLDE study [letter]. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161-6. JonesPW , WillitsLR , BurgePS , CalverleyPM . Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68-73. SpencerS , CalverleyPM , BurgePS , JonesPW . Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122-8. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698-702. ">Burge 2000</a>; <a href="./references#CD002991-bbs2-0019" title="AnthonisenNR , ConnettJC , MurrayRP . Smoking and lung function of Lung Health Study participants after 11 years. American Journal of Respiratory and Critical Care Medicine2002;166(5):675-9. EichenhornMS , WiseRA , MadhokTC , GeraldLB , BaileyWC , TashkinDP , et al. Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest2003;124(1):57-62. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New England Journal of Medicine2000;343(26):1902-9. ScanlonPD , ConnettJE , WiseRA , TashkinDP , MadhokT , SkeansM , et al. Loss of one density with inhaled triamcinolone in Lung Health Study II. American Journal of Respiratory and Critical Care Medicine2004;170(12):1302-9. TashkinDP , MurrayHE , SkeansM , MurrayRP . Skin manifestations of inhaled corticosteroids in COPD patients. Chest2004;126(4):1123-33. ">LHS 2000</a>; <a href="./references#CD002991-bbs2-0033" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819-23. [MEDLINE: 99285938]">Vestbo 1999</a>; <a href="./references#CD002991-bbs2-0034" title="VestboJ , AndersonJA , BrookRD , CalverleyPM , CelliBR , CrimC , et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet2016;387:1817-26. ">Vestbo 2016</a>; <a href="./references#CD002991-bbs2-0035" title="WeirDC , BaleGA , BrightP , Sherwood BurgeP . A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy Supplement1999;29(2):125-8. ">Weir 1999</a>). <a href="./references#CD002991-bbs2-0025" title="JohnellO , PauwelsR , Löfdahl C-G, LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. European Respiratory Journal2002;19(6):1058-63. LofdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467-72. PauwelsRA , LofdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of Medicine1999;340(25):1948-53. PauwelsRA , LofdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254-61. ">Pauwels 1999</a> (1277 participants) found no difference between the median decline of FEV<sub>1</sub> of 57 mL/year in the BUD group and 69 mL/year in the placebo group. </p> <div class="figure" id="CD002991-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot (1.8 Postbronchodilator FEV1 – Difference in rate of decline)." data-id="CD002991-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot (1.8 Postbronchodilator FEV<sub>1</sub> – Difference in rate of decline). </p> </div> </div> </div> <p>When analysing means for the ICS versus placebo groups, the pooled difference in rate of decline in postbronchodilator FEV<sub>1</sub> in six studies was 7.28 mL/year (95% CI 3.21 to 11.35; I<sup>2</sup> = 0%; 12,502 participants; moderate‐certainty evidence; <a href="./references#CD002991-fig-0016" title="">Analysis 1.9</a>; <a href="#CD002991-fig-0006">Figure 6</a>) (<a href="./references#CD002991-bbs2-0003" title="BaleG , Martinez-CamblorP , BurgePS , SorianoJB . Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468-72. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297-303. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654-8. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659-64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW . Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350. D'UrzoAD , CalverleyPM . Withdrawal of treatment in the ISOLDE study [letter]. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161-6. JonesPW , WillitsLR , BurgePS , CalverleyPM . Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68-73. SpencerS , CalverleyPM , BurgePS , JonesPW . Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122-8. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698-702. ">Burge 2000</a>; <a href="./references#CD002991-bbs2-0111" title="CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332-8.">Celli 2008</a>; <a href="./references#CD002991-bbs2-0019" title="AnthonisenNR , ConnettJC , MurrayRP . Smoking and lung function of Lung Health Study participants after 11 years. American Journal of Respiratory and Critical Care Medicine2002;166(5):675-9. EichenhornMS , WiseRA , MadhokTC , GeraldLB , BaileyWC , TashkinDP , et al. Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest2003;124(1):57-62. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New England Journal of Medicine2000;343(26):1902-9. ScanlonPD , ConnettJE , WiseRA , TashkinDP , MadhokT , SkeansM , et al. Loss of one density with inhaled triamcinolone in Lung Health Study II. American Journal of Respiratory and Critical Care Medicine2004;170(12):1302-9. TashkinDP , MurrayHE , SkeansM , MurrayRP . Skin manifestations of inhaled corticosteroids in COPD patients. Chest2004;126(4):1123-33. ">LHS 2000</a>; <a href="./references#CD002991-bbs2-0027" title="ChavannesNH , SchermerTR , WoutersEF , AkkermansRP , DekhuijzenRP , MurisJW , et al. Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International Journal of COPD2009;4:431-6. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103(4):542-51. ">Schermer 2009</a>; <a href="./references#CD002991-bbs2-0029" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , MaltbaekN , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD2009;6(2):104-11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD2011;8(1):2-7. ">Shaker 2009</a>; <a href="./references#CD002991-bbs2-0034" title="VestboJ , AndersonJA , BrookRD , CalverleyPM , CelliBR , CrimC , et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet2016;387:1817-26. ">Vestbo 2016</a>). The study that contributed the most weight to this difference was the SUMMIT study, which reported a mean 38 mL/year decline in FEV<sub>1</sub> for the FF 100 µg/day group compared to 46 mL/year decline for the placebo group (<a href="./references#CD002991-bbs2-0034" title="VestboJ , AndersonJA , BrookRD , CalverleyPM , CelliBR , CrimC , et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet2016;387:1817-26. ">Vestbo 2016</a>). Of note in the SUMMIT trial, the combination fluticasone/vilanterol group recorded an equivalent mean of 38 mL/year decline, similar to the FF only group, while the vilanterol group recorded a 47 mL/year decline in FEV<sub>1</sub> (<a href="./references#CD002991-bbs2-0034" title="VestboJ , AndersonJA , BrookRD , CalverleyPM , CelliBR , CrimC , et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet2016;387:1817-26. ">Vestbo 2016</a>). Similarly, the TORCH study showed a difference for the ICS alone group (FP 1000 µg/day, 42 mL/year decline) versus placebo (55 mL/year decline); however, salmeterol (42 mL/year decline) and salmeterol/FP (39 mL/year decline) showed similar benefits in the rate of decline of FEV<sub>1</sub> (<a href="./references#CD002991-bbs2-0006" title="CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppl 5):A149 [PS-3-8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719-25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775-89. CalverleyPM , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , VestboJ , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD Health (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O-9-2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. San Francisco, California, USA, 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317-22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332-8. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB . Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456-65. FergusonGT , CalverleyPM , AndersonJA . The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. GSK-SCO30003. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.gsk-studyregister.com/en/trial-details/?id=SCO30003#documents-section (first received 7 September 2000). JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research2009;10:59. MehtaRS , KathmanSJ , Daley-YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long-term twice-daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:Poster #A41. The TORCH study group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206-10. ">Calverley 2007</a>). A subgroup analysis of ICS dose found no evidence of a difference between studies that tested ICS doses  of BDP 1000 µg equivalent per day or greater compared with less than 1000 µg per day, although the effect was numerically larger in the high‐dose subgroup  (high dose: MD 11.58 mL/year, 95% CI 4.57 to 18.60; 3281 participants; low dose: MD 5.11 mL/year, 95% CI 0.11 to 10.10; 9221 participants; test for subgroup differences: Chi<sup>2</sup> = 2.17, degrees of freedom (df) = 1, P = 0.14) (<a href="#CD002991-fig-0006">Figure 6</a>). participants;  </p> <div class="figure" id="CD002991-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot (1.9 Change in postbronchodilator FEV1 (mL/year)." data-id="CD002991-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot (1.9 Change in postbronchodilator FEV<sub>1</sub> (mL/year). </p> </div> </div> </div> <p><a href="./references#CD002991-bbs2-0017" title="LapperreTS , Snoeck-StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517-27. ">Lapperre 2009</a> demonstrated a difference in rate of decline of FEV<sub>1</sub> (MD 86.30 mL/year, 95% CI 43.02 to 129.58); however, this result was not pooled because the rate of decline measured was from six months to 30 months of treatment, instead of from baseline. </p> </section> <section id="CD002991-sec-0068"> <h5 class="title">All‐cause mortality</h5> <p>Ten long‐term studies reported all‐cause mortality (<a href="#CD002991-fig-0007">Figure 7</a>). The overall OR for mortality for all 10 studies was 0.94 (95% CI 0.84 to 1.07; I<sup>2</sup> = 0%; 16,633 participants; moderate‐certainty evidence; <a href="./references#CD002991-fig-0014" title="">Analysis 1.7</a>). A test for subgroup differences between studies that tested high‐dose ICS (1000 µg or greater versus less than BDP 1000 µg equivalent of ICS per day) found difference between subgroups (Chi<sup>2</sup> = 1.35, df = 1, P = 0.25).  </p> <div class="figure" id="CD002991-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot (1.7 Mortality)." data-id="CD002991-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot (1.7 Mortality).</p> </div> </div> </div> </section> <section id="CD002991-sec-0069"> <h5 class="title">Use of rescue bronchodilators</h5> <p>Only one long‐term study analysed rescue bronchodilator use. In this study, there was difference in use of reliever medication with ICS (<a href="./references#CD002991-bbs2-0005" title="BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912-9. CalverleyPM , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P436. CalverleyPM , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. CalverleyPM , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:B024 Poster 418. CalverleyPM , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:D092 Poster 211. CalverleyPM , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. In: American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego. 2005. CalverleyPM , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. In: American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando. 2004. HalpinDMG , LarssonT , CalverleyPM . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. In: American Thoracic Society 2005 International Conference; May 20-25; San Diego. 2005. JonesPW , StåhlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [Abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health-related quality of life in patients with COPD. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365-75. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14-21. ">Calverley 2003b</a>). </p> </section> <section id="CD002991-sec-0070"> <h5 class="title">Exercise capacity</h5> <p>One long‐term study measured shuttle walking test but there were insufficient details to permit an analysis (<a href="./references#CD002991-bbs2-0011" title="GSK-SCO30002. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. www.gsk-studyregister.com/en/trial-details/?id=SCO30002 (first received 11 January 2006). ">GSK‐SCO30002</a>). </p> </section> </section> <section id="CD002991-sec-0071"> <h4 class="title">Short‐term studies (three  to six months)</h4> <section id="CD002991-sec-0072"> <h5 class="title">Exacerbations of chronic obstructive pulmonary disease</h5> <p>We pooled results for number of participants with at least one exacerbation for eight short‐term studies (<a href="./references#CD002991-bbs2-0010" title="FLTA3025. A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250mcg BID, 500mcg BID, and placebo BID via the DISKUS in subjects with chronic obstructive pulmonary disease (COPD). www.gsk-studyregister.com/en/trial-details/?id=FLTA3025 (first received 8 August 1998). ">GSK FLTA3025</a>; <a href="./references#CD002991-bbs2-0012" title="GSK SFCA3007. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3007 (first received 10 November 1998). HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834-43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine2001;163(Suppl 5):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22(Suppl 45):P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. In: US COPD Coalition National COPD Conference 2003; Nov 14-15, Arlington. 2003:1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P429. ">GSK SFCA3007</a>; <a href="./references#CD002991-bbs2-0016" title="KerwinEM , Scott-WilsonC , SanfordL , RennardS , AgustiA , BarnesN , et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respiratory Medicine2013;107:560-9. ">Kerwin 2013</a>; <a href="./references#CD002991-bbs2-0018" title="LaptsevaIM , LaptsevaEA , BorshchevskyVV , GurevichG , KalechitsO . Inhaled budesonide in the management of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):244s. ">Laptseva 2002</a>; <a href="./references#CD002991-bbs2-0020" title="GSK SFCA3006. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3006 (first accessed 24 September 1998). MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). www.abstracts2view.com (accessed prior to 9 September 2022). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084-91. ">Mahler 2002</a>; <a href="./references#CD002991-bbs2-0021" title="MartinezFJ , BosciaJ , FeldmanG , Scott-WilsonC , KilbrideS , FabbriL , et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respiratory Medicine2013;107:550-9. ">Martinez 2013</a>; <a href="./references#CD002991-bbs2-0024" title="FLIT97. A multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000µg daily with placebo in chronic obstructive pulmonary disease. ctr.gsk.co.uk2005. PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773-80. ">Paggiaro 1998</a>; <a href="./references#CD002991-bbs2-0032" title="TashkinDP , DohertyDE , KerwinE , Matiz-BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73-86. ">Tashkin 2012</a>). Three studies reported only moderate or severe exacerbations (<a href="./references#CD002991-bbs2-0016" title="KerwinEM , Scott-WilsonC , SanfordL , RennardS , AgustiA , BarnesN , et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respiratory Medicine2013;107:560-9. ">Kerwin 2013</a>; <a href="./references#CD002991-bbs2-0018" title="LaptsevaIM , LaptsevaEA , BorshchevskyVV , GurevichG , KalechitsO . Inhaled budesonide in the management of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):244s. ">Laptseva 2002</a>; <a href="./references#CD002991-bbs2-0021" title="MartinezFJ , BosciaJ , FeldmanG , Scott-WilsonC , KilbrideS , FabbriL , et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respiratory Medicine2013;107:550-9. ">Martinez 2013</a>), while the remaining five studies analysed all severities of exacerbations. The pooled OR for having at least one exacerbation during the study period was 0.84 for ICS compared to placebo (95% CI 0.66 to 1.06; 2159 participants; <a href="./references#CD002991-fig-0032" title="">Analysis 2.1</a>). Several studies reported change in number of exacerbations although not in sufficient detail to pool (<a href="./references#CD002991-bbs2-0001" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477-82. ">Bourbeau 1998</a>; <a href="./references#CD002991-bbs2-0013" title="GizyckiMJ , HattotuwaKL , BarnesN , JefferyPK . Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax2002;57(9):799-803. HattotuwaKL , GizyckiMJ , AnsariTW , JefferyPK , BarnesNC . The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;165(12):1592-9. ">Hattotuwa 2002</a>; <a href="./references#CD002991-bbs2-0028" title="SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respiratory Medicine1999;93(10):715-8. ">Senderovitz 1999</a>). </p> </section> <section id="CD002991-sec-0073"> <h5 class="title">Quality of life</h5> <p>Quality of life improved with ICS, as measured by the SGRQ total and activity scores (<a href="./references#CD002991-bbs2-0032" title="TashkinDP , DohertyDE , KerwinE , Matiz-BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73-86. ">Tashkin 2012</a>; <a href="./references#CD002991-bbs2-0036" title="YildizF , BasyigitI , YildirimE , BoyaciH , IlgazliA . Does addition of inhaled steroids to combined bronchodilator therapy affect health status in patients with COPD?Respirology2004;9(3):352-5. ">Yildiz 2004</a>), SGRQ symptoms score (<a href="./references#CD002991-bbs2-0014" title="JohnM , BosseS , OltmannsU , SchumacherA , WittC . Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respiratory Medicine2005;99(11):1418-24. JohnM , BosseS , SchumacherA , OltmannsU , WittC . Effects of inhaled beclomethasone HFA 134 (qvar/ventoiair) on health related quality of life in patients with chronic obstructive pulmonary disease [Abstract]. In: American Thoracic Society International Conference; 2005 May 20-25; San Diego. 2005:Poster A43. ">John 2005</a>), and the Chronic Respiratory Questionnaire (<a href="./references#CD002991-bbs2-0012" title="GSK SFCA3007. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3007 (first received 10 November 1998). HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834-43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine2001;163(Suppl 5):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22(Suppl 45):P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. In: US COPD Coalition National COPD Conference 2003; Nov 14-15, Arlington. 2003:1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P429. ">GSK SFCA3007</a>; <a href="./references#CD002991-bbs2-0020" title="GSK SFCA3006. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3006 (first accessed 24 September 1998). MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). www.abstracts2view.com (accessed prior to 9 September 2022). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084-91. ">Mahler 2002</a>). There were no changes in health‐related quality of life measured using the Chronic Respiratory Questionnaire in one study (<a href="./references#CD002991-bbs2-0001" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477-82. ">Bourbeau 1998</a>). </p> <p>Several short‐term studies reported results of symptom scores, but numerical data were generally not given in sufficient detail to pool. Cough improved in two studies (<a href="./references#CD002991-bbs2-0013" title="GizyckiMJ , HattotuwaKL , BarnesN , JefferyPK . Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax2002;57(9):799-803. HattotuwaKL , GizyckiMJ , AnsariTW , JefferyPK , BarnesNC . The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;165(12):1592-9. ">Hattotuwa 2002</a>; <a href="./references#CD002991-bbs2-0024" title="FLIT97. A multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000µg daily with placebo in chronic obstructive pulmonary disease. ctr.gsk.co.uk2005. PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773-80. ">Paggiaro 1998</a>). Dyspnoea improved in one study (<a href="./references#CD002991-bbs2-0020" title="GSK SFCA3006. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3006 (first accessed 24 September 1998). MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). www.abstracts2view.com (accessed prior to 9 September 2022). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084-91. ">Mahler 2002</a>), and was unchanged in three studies (<a href="./references#CD002991-bbs2-0012" title="GSK SFCA3007. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3007 (first received 10 November 1998). HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834-43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine2001;163(Suppl 5):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22(Suppl 45):P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. In: US COPD Coalition National COPD Conference 2003; Nov 14-15, Arlington. 2003:1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P429. ">GSK SFCA3007</a>; <a href="./references#CD002991-bbs2-0013" title="GizyckiMJ , HattotuwaKL , BarnesN , JefferyPK . Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax2002;57(9):799-803. HattotuwaKL , GizyckiMJ , AnsariTW , JefferyPK , BarnesNC . The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;165(12):1592-9. ">Hattotuwa 2002</a>; <a href="./references#CD002991-bbs2-0024" title="FLIT97. A multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000µg daily with placebo in chronic obstructive pulmonary disease. ctr.gsk.co.uk2005. PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773-80. ">Paggiaro 1998</a>). Sputum symptom score improved in two studies (<a href="./references#CD002991-bbs2-0013" title="GizyckiMJ , HattotuwaKL , BarnesN , JefferyPK . Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax2002;57(9):799-803. HattotuwaKL , GizyckiMJ , AnsariTW , JefferyPK , BarnesNC . The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;165(12):1592-9. ">Hattotuwa 2002</a>; <a href="./references#CD002991-bbs2-0024" title="FLIT97. A multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000µg daily with placebo in chronic obstructive pulmonary disease. ctr.gsk.co.uk2005. PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773-80. ">Paggiaro 1998</a>), whereas chronic bronchitis symptoms were unchanged in two studies (<a href="./references#CD002991-bbs2-0012" title="GSK SFCA3007. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3007 (first received 10 November 1998). HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834-43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine2001;163(Suppl 5):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22(Suppl 45):P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. In: US COPD Coalition National COPD Conference 2003; Nov 14-15, Arlington. 2003:1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P429. ">GSK SFCA3007</a>; <a href="./references#CD002991-bbs2-0020" title="GSK SFCA3006. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3006 (first accessed 24 September 1998). MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). www.abstracts2view.com (accessed prior to 9 September 2022). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084-91. ">Mahler 2002</a>). Symptoms in general did not change in two studies (<a href="./references#CD002991-bbs2-0001" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477-82. ">Bourbeau 1998</a>; <a href="./references#CD002991-bbs2-0028" title="SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respiratory Medicine1999;93(10):715-8. ">Senderovitz 1999</a>). </p> </section> <section id="CD002991-sec-0074"> <h5 class="title">Lung function</h5> <p>Using the generic inverse variance function, we performed pooling for change in prebronchodilator FEV<sub>1</sub> in seven short‐term studies (<a href="./references#CD002991-bbs2-0001" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477-82. ">Bourbeau 1998</a>; <a href="./references#CD002991-bbs2-0012" title="GSK SFCA3007. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3007 (first received 10 November 1998). HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834-43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine2001;163(Suppl 5):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22(Suppl 45):P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. In: US COPD Coalition National COPD Conference 2003; Nov 14-15, Arlington. 2003:1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P429. ">GSK SFCA3007</a>; <a href="./references#CD002991-bbs2-0013" title="GizyckiMJ , HattotuwaKL , BarnesN , JefferyPK . Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax2002;57(9):799-803. HattotuwaKL , GizyckiMJ , AnsariTW , JefferyPK , BarnesNC . The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;165(12):1592-9. ">Hattotuwa 2002</a>; <a href="./references#CD002991-bbs2-0016" title="KerwinEM , Scott-WilsonC , SanfordL , RennardS , AgustiA , BarnesN , et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respiratory Medicine2013;107:560-9. ">Kerwin 2013</a>; <a href="./references#CD002991-bbs2-0020" title="GSK SFCA3006. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3006 (first accessed 24 September 1998). MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). www.abstracts2view.com (accessed prior to 9 September 2022). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084-91. ">Mahler 2002</a>; <a href="./references#CD002991-bbs2-0021" title="MartinezFJ , BosciaJ , FeldmanG , Scott-WilsonC , KilbrideS , FabbriL , et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respiratory Medicine2013;107:550-9. ">Martinez 2013</a>; <a href="./references#CD002991-bbs2-0032" title="TashkinDP , DohertyDE , KerwinE , Matiz-BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73-86. ">Tashkin 2012</a>). The mean change in FEV<sub>1</sub> was MD 0.04 L in favour of ICS (95% CI 0.02 to 0.06; 2427 participants; <a href="./references#CD002991-fig-0037" title="">Analysis 2.6</a>). Pooling of change in postbronchodilator FEV<sub>1</sub> from three short‐term studies showed an MD of 0.09 L in favour of ICS (95% CI −0.01 to 0.18; <a href="./references#CD002991-fig-0035" title="">Analysis 2.4</a>). Generic inverse variance analysis of postbronchodilator FEV<sub>1</sub> of five studies demonstrated an MD of 0.09 L in favour of ICS (95% CI 0.05 to 0.13; <a href="./references#CD002991-fig-0036" title="">Analysis 2.5</a>) (<a href="./references#CD002991-bbs2-0012" title="GSK SFCA3007. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3007 (first received 10 November 1998). HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834-43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine2001;163(Suppl 5):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22(Suppl 45):P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. In: US COPD Coalition National COPD Conference 2003; Nov 14-15, Arlington. 2003:1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P429. ">GSK SFCA3007</a>; <a href="./references#CD002991-bbs2-0016" title="KerwinEM , Scott-WilsonC , SanfordL , RennardS , AgustiA , BarnesN , et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respiratory Medicine2013;107:560-9. ">Kerwin 2013</a>; <a href="./references#CD002991-bbs2-0020" title="GSK SFCA3006. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3006 (first accessed 24 September 1998). MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). www.abstracts2view.com (accessed prior to 9 September 2022). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084-91. ">Mahler 2002</a>; <a href="./references#CD002991-bbs2-0021" title="MartinezFJ , BosciaJ , FeldmanG , Scott-WilsonC , KilbrideS , FabbriL , et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respiratory Medicine2013;107:550-9. ">Martinez 2013</a>; <a href="./references#CD002991-bbs2-0024" title="FLIT97. A multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000µg daily with placebo in chronic obstructive pulmonary disease. ctr.gsk.co.uk2005. PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773-80. ">Paggiaro 1998</a>). Other studies could not be pooled due to presentation of data as percent increase (<a href="./references#CD002991-bbs2-0022" title="MiriciA , BektasY , OzbakisG , ErmanZ . Effect of inhaled corticosteroids on respiratory function tests and airway inflammation in stable chronic obstructive pulmonary disease. Clinical Drug Investigation2001;21(12):835-42. ">Mirici 2001</a>), pretreatment and post‐treatment (<a href="./references#CD002991-bbs2-0014" title="JohnM , BosseS , OltmannsU , SchumacherA , WittC . Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respiratory Medicine2005;99(11):1418-24. JohnM , BosseS , SchumacherA , OltmannsU , WittC . Effects of inhaled beclomethasone HFA 134 (qvar/ventoiair) on health related quality of life in patients with chronic obstructive pulmonary disease [Abstract]. In: American Thoracic Society International Conference; 2005 May 20-25; San Diego. 2005:Poster A43. ">John 2005</a>; <a href="./references#CD002991-bbs2-0023" title="OzolD , AysanT , SolakZA , MogulkocN , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respiratory Medicine2005;99(12):1494-500. ">Ozol 2005</a>; <a href="./references#CD002991-bbs2-0036" title="YildizF , BasyigitI , YildirimE , BoyaciH , IlgazliA . Does addition of inhaled steroids to combined bronchodilator therapy affect health status in patients with COPD?Respirology2004;9(3):352-5. ">Yildiz 2004</a>), medians (<a href="./references#CD002991-bbs2-0028" title="SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respiratory Medicine1999;93(10):715-8. ">Senderovitz 1999</a>), or summary statement without data (<a href="./references#CD002991-bbs2-0018" title="LaptsevaIM , LaptsevaEA , BorshchevskyVV , GurevichG , KalechitsO . Inhaled budesonide in the management of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):244s. ">Laptseva 2002</a>). </p> </section> <section id="CD002991-sec-0075"> <h5 class="title">All‐cause mortality</h5> <p>Seven short‐term studies reported all‐cause mortality (<a href="./references#CD002991-bbs2-0009" title="FCO30002. A multicentre, randomised, placebo-controlled, double-blind comparison with 3 parallel groups to investigate the efficacy and safety of inhaled glucocorticoid fluticasone (500 μg bd via Diskus™) vs. oral glucocorticoid therapy vs. placebo in subjects with chronic obstructive airway disease (COPD) under therapy with salmeterol (50 μg bd). GlaxoSmithKline Clinical Trial Register2005. ">GSK FCO30002</a>; <a href="./references#CD002991-bbs2-0010" title="FLTA3025. A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250mcg BID, 500mcg BID, and placebo BID via the DISKUS in subjects with chronic obstructive pulmonary disease (COPD). www.gsk-studyregister.com/en/trial-details/?id=FLTA3025 (first received 8 August 1998). ">GSK FLTA3025</a>; <a href="./references#CD002991-bbs2-0012" title="GSK SFCA3007. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3007 (first received 10 November 1998). HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834-43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine2001;163(Suppl 5):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22(Suppl 45):P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. In: US COPD Coalition National COPD Conference 2003; Nov 14-15, Arlington. 2003:1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P429. ">GSK SFCA3007</a>; <a href="./references#CD002991-bbs2-0013" title="GizyckiMJ , HattotuwaKL , BarnesN , JefferyPK . Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax2002;57(9):799-803. HattotuwaKL , GizyckiMJ , AnsariTW , JefferyPK , BarnesNC . The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;165(12):1592-9. ">Hattotuwa 2002</a>; <a href="./references#CD002991-bbs2-0016" title="KerwinEM , Scott-WilsonC , SanfordL , RennardS , AgustiA , BarnesN , et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respiratory Medicine2013;107:560-9. ">Kerwin 2013</a>; <a href="./references#CD002991-bbs2-0020" title="GSK SFCA3006. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3006 (first accessed 24 September 1998). MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). www.abstracts2view.com (accessed prior to 9 September 2022). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084-91. ">Mahler 2002</a>; <a href="./references#CD002991-bbs2-0021" title="MartinezFJ , BosciaJ , FeldmanG , Scott-WilsonC , KilbrideS , FabbriL , et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respiratory Medicine2013;107:550-9. ">Martinez 2013</a>). Pooling of the total number of deaths showed an OR of 0.20 with ICS compared to placebo (95% CI 0.05 to 0.82; 2549 participants; <a href="./references#CD002991-fig-0038" title="">Analysis 2.7</a>). </p> </section> <section id="CD002991-sec-0076"> <h5 class="title">Use of rescue bronchodilators</h5> <p>Two studies reported reduced rescue bronchodilator usage (<a href="./references#CD002991-bbs2-0013" title="GizyckiMJ , HattotuwaKL , BarnesN , JefferyPK . Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax2002;57(9):799-803. HattotuwaKL , GizyckiMJ , AnsariTW , JefferyPK , BarnesNC . The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;165(12):1592-9. ">Hattotuwa 2002</a>; <a href="./references#CD002991-bbs2-0020" title="GSK SFCA3006. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. www.gsk-studyregister.com/en/trial-details/?id=SFCA3006 (first accessed 24 September 1998). MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). www.abstracts2view.com (accessed prior to 9 September 2022). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084-91. ">Mahler 2002</a>), and one study reported no difference (<a href="./references#CD002991-bbs2-0031" title="TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs2008;68(14):1975-2000. ">Tashkin 2008</a>). </p> </section> <section id="CD002991-sec-0077"> <h5 class="title">Exercise capacity</h5> <p>There was significant heterogeneity in change in six‐minute walk distance between the two short‐term studies that measured exercise capacity (<a href="./references#CD002991-bbs2-0001" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477-82. ">Bourbeau 1998</a>; <a href="./references#CD002991-bbs2-0024" title="FLIT97. A multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000µg daily with placebo in chronic obstructive pulmonary disease. ctr.gsk.co.uk2005. PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773-80. ">Paggiaro 1998</a>). When we pooled these data, there was no difference between ICS and placebo (MD −4.36 m, 95% CI −50.42 to 41.70; <a href="./references#CD002991-fig-0041" title="">Analysis 2.10</a>). </p> </section> </section> <section id="CD002991-sec-0078"> <h4 class="title">Adverse events (short‐ and long‐term studies)</h4> <section id="CD002991-sec-0079"> <h5 class="title">Pneumonia</h5> <section id="CD002991-sec-0080"> <h6 class="title">Long<i>‐</i>term studies (longer than six months) </h6> <p>In eight long‐term studies that reported pneumonia as an adverse event, the rate of pneumonia was increased in the ICS group compared to placebo (OR 1.38, 95% CI 1.02 to 1.88; I<sup>2</sup> = 55%; 14,831 participants; low‐certainty evidence; <a href="./references#CD002991-fig-0018" title="">Analysis 1.11</a>). A subgroup analysis of pneumonia based on ICS dosage (1000 µg or greater versus less than BDP 1000 µg equivalent of ICS per day) suggests that ICS doses of 1000 µg or greater BDP equivalent/day may have a higher risk than doses lower than BDP 1000 µg equivalent/day (higher‐dose subgroup: OR 1.65, 95% CI 1.37 to 1.99; 5285 participants; lower‐dose subgroup: OR 1.05, 95% CI 0.69 to 1.60; 9546 participants; test for subgroup difference Chi² = 3.72, df = 1, P = 0.05; <a href="./references#CD002991-fig-0018" title="">Analysis 1.11</a>). </p> </section> </section> <section id="CD002991-sec-0081"> <h5 class="title">Local corticosteroid adverse events</h5> <section id="CD002991-sec-0082"> <h6 class="title">Long<i>‐</i>term studies (longer than six months) </h6> <p>Pooling of data in the long‐term studies showed an increased risk of oropharyngeal candidiasis with ICS (OR 2.66, 95% CI 1.91 to 3.68; 5547 participants; <a href="./references#CD002991-fig-0022" title="">Analysis 1.15</a>). For participants randomised to less than BDP 1000 µg/day equivalent, this gave a number needed to treat for an additional harmful effect (NNTH) of 34. In studies assessing BDP 1000 µg/day or greater equivalent, there was some variation in baseline risk. In participants from the control group of <a href="./references#CD002991-bbs2-0003" title="BaleG , Martinez-CamblorP , BurgePS , SorianoJB . Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468-72. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297-303. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654-8. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659-64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW . Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350. D'UrzoAD , CalverleyPM . Withdrawal of treatment in the ISOLDE study [letter]. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161-6. JonesPW , WillitsLR , BurgePS , CalverleyPM . Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68-73. SpencerS , CalverleyPM , BurgePS , JonesPW . Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122-8. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698-702. ">Burge 2000</a>, risk was around 7%, and the NNTH for participants randomised to corticosteroid was 13 (95% CI 7 to 34), whereas in <a href="./references#CD002991-bbs2-0004" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449-56. CalverleyPM , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. www.abstracts2view.com (accessed prior to 11 March 2022). CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). GSK-SFCB3024. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. www.gsk-studyregister.com/en/trial-details/?id=SFCB3024 (first received 1 August 1998). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004:D22 Poster 503. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference [A39] [Poster K39]. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPM , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003:P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist2004;45(6):727-8. PauwelsRA , CalverlyPM , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1569]. PauwelsRA , VestboJ , CalverleyPM , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619-37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPM , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301-4. VestboJ , PauwelsRA , CalverleyPM , JonesPW , PrideNB , GulsvikA . Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045-50. ">Calverley 2003a</a>, the control group event rate was 1.4%, giving an NNTH of 57 (95% CI 29 to 156). In <a href="./references#CD002991-bbs2-0007" title="CalverleyP , PauwelsR , NieminemM , StryszakP , StaudingerH , LeeT . Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003:P155. CalverleyPM , RennardS , NelsonHS , KarpelJP , AbbateEH , StryszakP , et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respiratory Research2008;9:73. [1465-993X: (Electronic)] NelsonH , KarpelJP , StaudingerH , BusseWW . Mometasone furoate dry powder inhaler (MF-DPI) improves FEV1, symptoms, quality of life and reduces exacerbations in patients with COPD. Chest2004;236(4 Suppl):709s-10s. ">Calverley 2008</a>, the event rate was 11% amongst participants randomised to ICS giving an NNTH of 13. There was also an increased risk of hoarseness or dysphonia (OR 1.95, 95% CI 1.41 to 2.70; 3267 participants; <a href="./references#CD002991-fig-0023" title="">Analysis 1.16</a>). There was minimal heterogeneity, implying a consistent effect across the studies. </p> </section> <section id="CD002991-sec-0083"> <h6 class="title">Short‐term studies (three to six months)</h6> <p>Pooling of the short‐term studies showed an increased risk of oropharyngeal candidiasis (OR 3.91, 95% CI 1.67 to 9.17; 2928 participants; <a href="./references#CD002991-fig-0047" title="">Analysis 2.16</a>). Similarly, there was an increase in hoarseness or dysphonia (OR 3.56, 95% CI 1.74 to 7.30; 1314 participants; <a href="./references#CD002991-fig-0048" title="">Analysis 2.17</a>). There was a milder increase in throat irritation, although there was some heterogeneity between studies (OR 1.48, 95% CI 0.80 to 2.73; 1779 participants; <a href="./references#CD002991-fig-0046" title="">Analysis 2.15</a>). </p> </section> </section> <section id="CD002991-sec-0084"> <h5 class="title">Bone turnover and fractures</h5> <section id="CD002991-sec-0085"> <h6 class="title">Long‐term studies (longer than six months)</h6> <p>In the EUROSCOP study, there was no increased risk of vertebral fractures or osteoporosis in the participants treated with BUD (<a href="./references#CD002991-bbs2-0122" title="JohnellO , PauwelsR , LöfdahlCG , LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. European Respiratory Journal2002;19(6):1058-63.">Johnell 2002</a>; <a href="./references#CD002991-bbs2-0025" title="JohnellO , PauwelsR , Löfdahl C-G, LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. European Respiratory Journal2002;19(6):1058-63. LofdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467-72. PauwelsRA , LofdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of Medicine1999;340(25):1948-53. PauwelsRA , LofdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254-61. ">Pauwels 1999</a>). In the ISOLDE study, there was no increase in the rate of fractures of any type (<a href="./references#CD002991-bbs2-0109" title="BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654-8.">Burge 2003a</a>). In the LHS II, there was a reduction in bone mineral density in the lumbar spine and femoral neck in the group taking TAA compared to placebo (<a href="./references#CD002991-bbs2-0019" title="AnthonisenNR , ConnettJC , MurrayRP . Smoking and lung function of Lung Health Study participants after 11 years. American Journal of Respiratory and Critical Care Medicine2002;166(5):675-9. EichenhornMS , WiseRA , MadhokTC , GeraldLB , BaileyWC , TashkinDP , et al. Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest2003;124(1):57-62. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New England Journal of Medicine2000;343(26):1902-9. ScanlonPD , ConnettJE , WiseRA , TashkinDP , MadhokT , SkeansM , et al. Loss of one density with inhaled triamcinolone in Lung Health Study II. American Journal of Respiratory and Critical Care Medicine2004;170(12):1302-9. TashkinDP , MurrayHE , SkeansM , MurrayRP . Skin manifestations of inhaled corticosteroids in COPD patients. Chest2004;126(4):1123-33. ">LHS 2000</a>; <a href="./references#CD002991-bbs2-0128" title="ScanlonPD , ConnettJE , WiseRA , TashkinDP , MadhokT , SkeansM , et al. Loss of bone density with inhaled triamcinolone in Lung Health Study II. American Journal of Respiratory and Critical Care Medicine2004;170(12):1302-9.">Scanlon 2004</a>). In the TORCH study, there was no difference in rate of fractures between FP and placebo over three years, and, in one substudy, there was no difference in bone mineral density (<a href="./references#CD002991-bbs2-0006" title="CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppl 5):A149 [PS-3-8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719-25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775-89. CalverleyPM , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , VestboJ , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD Health (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O-9-2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. San Francisco, California, USA, 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317-22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332-8. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB . Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456-65. FergusonGT , CalverleyPM , AndersonJA . The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. GSK-SCO30003. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.gsk-studyregister.com/en/trial-details/?id=SCO30003#documents-section (first received 7 September 2000). JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research2009;10:59. MehtaRS , KathmanSJ , Daley-YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long-term twice-daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:Poster #A41. The TORCH study group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206-10. ">Calverley 2007</a>). Pooling of available data on fractures from studies of a duration of one year or longer found no increase in the risk of fractures (OR 1.00, 95% CI 0.81 to 1.24; 13,514 participants; <a href="./references#CD002991-fig-0028" title="">Analysis 1.21</a>). </p> </section> </section> <section id="CD002991-sec-0086"> <h5 class="title">Cortisol</h5> <section id="CD002991-sec-0087"> <h6 class="title">Long‐term studies (longer than six months)</h6> <p>Serum cortisol did not differ at the end of two years of therapy with BUD 1600 µg/day versus placebo (<a href="./references#CD002991-bbs2-0026" title="RenkemaTE , SchoutenJP , KoeterGH , PostmaDS . Effects of long-term treatment with corticosteroids in COPD. Chest1996;109(5):1156-62. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. ">Renkema 1996</a>). The number of participants whose serum cortisol changed from normal to below normal did not differ between FP 1000 µg/day versus placebo (<a href="./references#CD002991-bbs2-0004" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449-56. CalverleyPM , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. www.abstracts2view.com (accessed prior to 11 March 2022). CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). GSK-SFCB3024. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. www.gsk-studyregister.com/en/trial-details/?id=SFCB3024 (first received 1 August 1998). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004:D22 Poster 503. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference [A39] [Poster K39]. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPM , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003:P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist2004;45(6):727-8. PauwelsRA , CalverlyPM , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1569]. PauwelsRA , VestboJ , CalverleyPM , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619-37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPM , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301-4. VestboJ , PauwelsRA , CalverleyPM , JonesPW , PrideNB , GulsvikA . Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045-50. ">Calverley 2003a</a>). In the ISOLDE study, there was a small decrease in mean serum cortisol with FP compared to placebo (<a href="./references#CD002991-bbs2-0109" title="BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654-8.">Burge 2003a</a>). In the LHS II, TAA 1200 µg/day over three years did not suppress baseline cortisol level's function or diminish adrenal responsiveness to cosyntropin stimulation (<a href="./references#CD002991-bbs2-0115" title="EichenhornMS , WiseRA , MadhokTC , GeraldLB , BaileyWC , TashkinDP , et al. Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest2003;124(1):57-62.">Eichenhorn 2003</a>). </p> </section> <section id="CD002991-sec-0088"> <h6 class="title">Short‐term studies (three to six months)</h6> <p>Serum cortisol was lower with six months of FP 1000 µg/day compared to placebo (<a href="./references#CD002991-bbs2-0024" title="FLIT97. A multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000µg daily with placebo in chronic obstructive pulmonary disease. ctr.gsk.co.uk2005. PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773-80. ">Paggiaro 1998</a>). </p> </section> </section> <section id="CD002991-sec-0089"> <h5 class="title">Other adverse events</h5> <p>Skin bruising was increased with BUD in the EUROSCOP study (<a href="./references#CD002991-bbs2-0025" title="JohnellO , PauwelsR , Löfdahl C-G, LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. European Respiratory Journal2002;19(6):1058-63. LofdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467-72. PauwelsRA , LofdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of Medicine1999;340(25):1948-53. PauwelsRA , LofdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254-61. ">Pauwels 1999</a>), and there were trends to increased skin bruising in other long‐term studies (<a href="./references#CD002991-bbs2-0003" title="BaleG , Martinez-CamblorP , BurgePS , SorianoJB . Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468-72. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297-303. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654-8. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659-64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW . Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350. D'UrzoAD , CalverleyPM . Withdrawal of treatment in the ISOLDE study [letter]. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161-6. JonesPW , WillitsLR , BurgePS , CalverleyPM . Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68-73. SpencerS , CalverleyPM , BurgePS , JonesPW . Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122-8. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698-702. ">Burge 2000</a>; <a href="./references#CD002991-bbs2-0004" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449-56. CalverleyPM , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. www.abstracts2view.com (accessed prior to 11 March 2022). CalverleyPM , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). GSK-SFCB3024. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. www.gsk-studyregister.com/en/trial-details/?id=SFCB3024 (first received 1 August 1998). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004:D22 Poster 503. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference [A39] [Poster K39]. www.abstracts-on-line.com/abstracts/ATS (accessed prior to 11 March 2022). JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPM , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003:P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist2004;45(6):727-8. PauwelsRA , CalverlyPM , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1569]. PauwelsRA , VestboJ , CalverleyPM , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619-37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPM , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301-4. VestboJ , PauwelsRA , CalverleyPM , JonesPW , PrideNB , GulsvikA . Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. www.abstracts2view.com (accessed prior to 11 March 2022). VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045-50. ">Calverley 2003a</a>; <a href="./references#CD002991-bbs2-0007" title="CalverleyP , PauwelsR , NieminemM , StryszakP , StaudingerH , LeeT . Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS. In: European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003:P155. CalverleyPM , RennardS , NelsonHS , KarpelJP , AbbateEH , StryszakP , et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respiratory Research2008;9:73. [1465-993X: (Electronic)] NelsonH , KarpelJP , StaudingerH , BusseWW . Mometasone furoate dry powder inhaler (MF-DPI) improves FEV1, symptoms, quality of life and reduces exacerbations in patients with COPD. Chest2004;236(4 Suppl):709s-10s. ">Calverley 2008</a>; <a href="./references#CD002991-bbs2-0019" title="AnthonisenNR , ConnettJC , MurrayRP . Smoking and lung function of Lung Health Study participants after 11 years. American Journal of Respiratory and Critical Care Medicine2002;166(5):675-9. EichenhornMS , WiseRA , MadhokTC , GeraldLB , BaileyWC , TashkinDP , et al. Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest2003;124(1):57-62. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New England Journal of Medicine2000;343(26):1902-9. ScanlonPD , ConnettJE , WiseRA , TashkinDP , MadhokT , SkeansM , et al. Loss of one density with inhaled triamcinolone in Lung Health Study II. American Journal of Respiratory and Critical Care Medicine2004;170(12):1302-9. TashkinDP , MurrayHE , SkeansM , MurrayRP . Skin manifestations of inhaled corticosteroids in COPD patients. Chest2004;126(4):1123-33. ">LHS 2000</a>). Overall, the pooled OR for skin bruising with ICS was 1.70 (95% CI 1.33 to 2.17; 4778 participants). In the LHS, there was no overall difference in bruising or cataracts with TAA (<a href="./references#CD002991-bbs2-0019" title="AnthonisenNR , ConnettJC , MurrayRP . Smoking and lung function of Lung Health Study participants after 11 years. American Journal of Respiratory and Critical Care Medicine2002;166(5):675-9. EichenhornMS , WiseRA , MadhokTC , GeraldLB , BaileyWC , TashkinDP , et al. Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest2003;124(1):57-62. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New England Journal of Medicine2000;343(26):1902-9. ScanlonPD , ConnettJE , WiseRA , TashkinDP , MadhokT , SkeansM , et al. Loss of one density with inhaled triamcinolone in Lung Health Study II. American Journal of Respiratory and Critical Care Medicine2004;170(12):1302-9. TashkinDP , MurrayHE , SkeansM , MurrayRP . Skin manifestations of inhaled corticosteroids in COPD patients. Chest2004;126(4):1123-33. ">LHS 2000</a>). However, Tashkin and colleagues, as part of the LHS II, found that amongst those participants who were adherent to ICS, a higher proportion of participants reported easy bruising and slow healing of cuts or sores (<a href="./references#CD002991-bbs2-0019" title="AnthonisenNR , ConnettJC , MurrayRP . Smoking and lung function of Lung Health Study participants after 11 years. American Journal of Respiratory and Critical Care Medicine2002;166(5):675-9. EichenhornMS , WiseRA , MadhokTC , GeraldLB , BaileyWC , TashkinDP , et al. Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest2003;124(1):57-62. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New England Journal of Medicine2000;343(26):1902-9. ScanlonPD , ConnettJE , WiseRA , TashkinDP , MadhokT , SkeansM , et al. Loss of one density with inhaled triamcinolone in Lung Health Study II. American Journal of Respiratory and Critical Care Medicine2004;170(12):1302-9. TashkinDP , MurrayHE , SkeansM , MurrayRP . Skin manifestations of inhaled corticosteroids in COPD patients. Chest2004;126(4):1123-33. ">LHS 2000</a>). There was no increase in the rate of cataract formation in two studies (<a href="./references#CD002991-bbs2-0109" title="BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654-8.">Burge 2003a</a>; <a href="./references#CD002991-bbs2-0006" title="CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppl 5):A149 [PS-3-8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719-25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775-89. CalverleyPM , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , VestboJ , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD Health (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O-9-2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. San Francisco, California, USA, 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317-22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332-8. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB . Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456-65. FergusonGT , CalverleyPM , AndersonJA . The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. GSK-SCO30003. A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.gsk-studyregister.com/en/trial-details/?id=SCO30003#documents-section (first received 7 September 2000). JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research2009;10:59. MehtaRS , KathmanSJ , Daley-YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long-term twice-daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:Poster #A41. The TORCH study group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206-10. ">Calverley 2007</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002991-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002991-sec-0090"></div> <section id="CD002991-sec-0091"> <h3 class="title" id="CD002991-sec-0091">Summary of main results</h3> <p>This systematic review has updated the evidence from RCTs of ICS used as monotherapy for greater than 12 weeks, compared to placebo, in people with COPD. Four additional RCTs, which were published since our previous 2012 review, are now included in this updated review, adding to the evidence for the effects and adverse effects of ICS (<a href="./references#CD002991-bbs2-0016" title="KerwinEM , Scott-WilsonC , SanfordL , RennardS , AgustiA , BarnesN , et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respiratory Medicine2013;107:560-9. ">Kerwin 2013</a>; <a href="./references#CD002991-bbs2-0021" title="MartinezFJ , BosciaJ , FeldmanG , Scott-WilsonC , KilbrideS , FabbriL , et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respiratory Medicine2013;107:550-9. ">Martinez 2013</a>; <a href="./references#CD002991-bbs2-0032" title="TashkinDP , DohertyDE , KerwinE , Matiz-BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73-86. ">Tashkin 2012</a>; <a href="./references#CD002991-bbs2-0034" title="VestboJ , AndersonJA , BrookRD , CalverleyPM , CelliBR , CrimC , et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet2016;387:1817-26. ">Vestbo 2016</a>). The data from these additional studies changed the results of the pooled analysis for change in rate of lung function decline (likely reduction in FEV<sub>1</sub> decline rate, of uncertain clinical relevance), whereas they did not substantially alter the results of pooled analyses for exacerbations (likely reduction in exacerbation rates of clinical relevance), mortality (probably no  benefit) and health‐related quality of life (likely small improvement but not meeting the threshold for an MCID). For adverse events, ICS is likely to increase local oropharyngeal effects and may increase the risk of pneumonia.  </p> <p>Overall, in people with stable COPD, long‐term use of ICS as monotherapy, when compared to placebo, likely reduces the rate of clinically relevant COPD exacerbations, and probably slows the rate of decline of lung function (FEV<sub>1</sub>), although the magnitude of this change is of unclear clinical relevance. ICS as monotherapy likely results in a small improvement in health‐related quality of life measures without meeting the threshold for a clinically important difference but there is probably no reduction in all‐cause mortality. The potential benefits of ICS as monotherapy must be weighed against the potential adverse events such as a likely increase in the risk of pneumonia and local oropharyngeal candidiasis. </p> </section> <section id="CD002991-sec-0092"> <h3 class="title" id="CD002991-sec-0092">Overall completeness and applicability of evidence</h3> <p>Differences in outcome reporting in the various studies meant that several approaches were needed for some analyses. For the analysis of change in lung function, both generic inverse variance analysis and pooled means analysis were required, because of variations in lung function outcome reporting, and these approaches yielded numerically similar results. Similarly, results for exacerbation rates were reported in different ways in studies, necessitating several approaches for analysis. Mortality, quality of life and adverse effects were reported more uniformly. Quality of life was largely reported as the mean change of SGRQ scores rather than the proportion of participants achieving an MCID between groups. Although primary outcomes differed between studies, both primary and secondary outcomes from published RCTs of ICS for people with COPD were highly applicable to understanding benefits and risks of ICS. </p> <p>Our systematic review specifically focused on ICS as a monocomponent since, historically, RCTs from the 1980s onwards initially examined ICS alone as a potential intervention for COPD. Subsequently, as pharmacological therapy has evolved, additional agents in the form of long‐acting bronchodilators have been introduced and tested, and then combinations of these with ICS. The more efficacious combination therapies have long since superseded consideration of the use of ICS as a monotherapy for COPD. Nevertheless, it remains useful to evaluate the evidence base arising from those studies that have been performed that use ICS as monotherapy as the primary intervention, or subsequent studies that employed an ICS only arm as a comparator. </p> <p>Therefore, the ICS‐only studies reviewed here should be interpreted in the light of the newer studies using combination inhalers of LABA, LAMA and ICS, which are more effective than ICS alone in COPD. Nevertheless, this systematic review updates the evidence base for the effect of ICS as a monocomponent in COPD, to more broadly inform on clinical recommendations about the role of ICS overall for COPD. </p> </section> <section id="CD002991-sec-0093"> <h3 class="title" id="CD002991-sec-0093">Quality of the evidence</h3> <p>The evidence ranged from low to moderate certainty in this review. We have moderate confidence in the evidence for the findings related to COPD exacerbations, quality of life, lung function and mortality. This is due to imprecision in the data across these studies. We have low confidence in the evidence for pneumonia due to imprecision and heterogeneity across study data. There was wide variability in study characteristics, including dose and duration of ICS, severity of COPD, inclusion criteria (e.g. current or previous smoking history, BHR, bronchodilator reversibility) and outcomes studied. Furthermore, results for outcomes were sometimes either missing or could not be pooled (e.g. non‐parametric data; continuous versus categorical classification of similar outcomes such as change in FEV<sub>1</sub>). Subgroup analysis, whilst potentially useful, was not possible due to lack of individual data. With the use of the generic inverse variance function, it was possible to pool data for some studies. Most studies measured adverse effects, although even longer studies would probably be required to determine the rates of adverse effects such as vertebral fractures and cataracts. Finally, participants who withdrew from the placebo arm of the long‐term ICS studies may have been those participants who were deteriorating the most rapidly, which may underestimate the effect of active treatment (<a href="./references#CD002991-bbs2-0110" title="CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW . Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350.">Calverley 2003c</a>). </p> </section> <section id="CD002991-sec-0094"> <h3 class="title" id="CD002991-sec-0094">Potential biases in the review process</h3> <p>The systematic review has not undertaken comparisons between individual ICS agents because of the heterogeneity of study designs and patient populations in the studies. However, we have included sensitivity analysis of higher versus lower doses of ICS in all analyses.  </p> <p>We were able to include the SUMMIT study, which provided information on outcomes in people taking ICS as monotherapy, as a separate treatment arm, compared to placebo (<a href="./references#CD002991-bbs2-0034" title="VestboJ , AndersonJA , BrookRD , CalverleyPM , CelliBR , CrimC , et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet2016;387:1817-26. ">Vestbo 2016</a>). This study recruited people with moderate‐to‐severe COPD who also had known cardiovascular risk factors. Whilst this was a specific inclusion criteria, this patient population overlaps with patients with COPD who have comorbidities, and the demographics and clinical characteristics of the participants included in this study were within range of other similar studies. It is noted that SUMMIT was an event‐driven study, and outcomes were recorded for patients on treatment (especially measurements of lung function), which is a potential limitation but similar in procedures to other RCTs. The addition of the data from the SUMMIT study has now shown a result for change in lung function decline; however, the absolute difference remains fairly small and somewhat debatable. Inclusion of the SUMMIT study has also added to exacerbation and pneumonia data. </p> <p>Another aspect to note is the pooling of data of people with varying degrees of severity of COPD may dilute signals present in subsets of patients. For instance, people with severe COPD have a higher risk of certain outcomes such as exacerbations and death and these patients may benefit more from intervention such as ICS. Additionally, eosinophilia (a marker of airway inflammation and response to corticosteroid treatment) was not included in most studies but is an area that could be explored in future studies. </p> <p>We made several changes to the original protocol of this review for this review update, which may introduce bias (<a href="#CD002991-sec-0122">Differences between protocol and review</a>). These changes were made to include studies with a minimum of 12 weeks of study duration to enable time for meaningful changes in outcome data and exclude people who are more likely to have an asthma rather than COPD diagnosis. </p> </section> <section id="CD002991-sec-0095"> <h3 class="title" id="CD002991-sec-0095">Agreements and disagreements with other studies or reviews</h3> <p>The results of our systematic review may be compared to previous systematic reviews addressing the specific question of ICS versus placebo for COPD. <a href="#CD002991-tbl-0003">Table 2</a> summarises previously published meta‐analyses addressing ICS as monotherapy versus placebo and examining outcomes of clinical relevance to COPD (<a href="./references#CD002991-bbs2-0117" title="GartlehnerG , HansenRA , CarsonSS , LohrKN . Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Annals of Family Medicine2006;4(3):253-62.">Gartlehner 2006</a>; <a href="./references#CD002991-bbs2-0121" title="HighlandKB , StrangeC , HeffnerJE . Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: a meta-analysis. Annals of Internal Medicine2003;138(12):969-73.">Highland 2003</a>; <a href="./references#CD002991-bbs2-0121" title="HighlandKB , StrangeC , HeffnerJE . Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: a meta-analysis. Annals of Internal Medicine2003;138(12):969-73.">Highland 2003</a>; <a href="./references#CD002991-bbs2-0129" title="SinDD , WuL , AndersonJA , AnthonisenNR , BuistAS , BurgePS , et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax2005;60(12):992-7.">Sin 2005</a>; <a href="./references#CD002991-bbs2-0130" title="SinghS , AminAV , LokeYK . Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Archives of Internal Medicine2009;169(3):219-29.">Singh 2009</a>; <a href="./references#CD002991-bbs2-0131" title="SorianoJB , SinDD , ZhangX , AndersonJA , AnthonisenNR , BuistAS , et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest2007;131:682-9.">Soriano 2007</a>; <a href="./references#CD002991-bbs2-0131" title="SorianoJB , SinDD , ZhangX , AndersonJA , AnthonisenNR , BuistAS , et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest2007;131:682-9.">Soriano 2007</a>; <a href="./references#CD002991-bbs2-0133" title="vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. [DOI: 10.1136/thx.54.1.7]">van Grunsven 1999</a>). These meta‐analyses have generally shown some similarities to the findings in ours; however, our systematic review now includes several new studies that were not included in the previous meta‐analyses. </p> <div class="table" id="CD002991-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Published meta‐analyses of ICS versus placebo for stable chronic obstructive pulmonary disease</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Reference</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Year</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Results for ICS as monocomponent (compared to placebo)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0133" title="vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. [DOI: 10.1136/thx.54.1.7]">van Grunsven 1999</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of decline in prebronchodilator FEV<sub>1</sub> +34 mL/year (95% CI 5 to 63)<br/>No difference in exacerbation rate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data included in this current review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0121" title="HighlandKB , StrangeC , HeffnerJE . Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: a meta-analysis. Annals of Internal Medicine2003;138(12):969-73.">Highland 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of decline in pre‐ or postbronchodilator FEV<sub>1</sub> +5.31 (SD 3.0) mL/year (P = 0.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0132" title="SutherlandER , AllmersH , AyasNT , VennAJ , MartinRJ . Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax2003;58(11):937-41.">Sutherland 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of decline in postbronchodilator FEV<sub>1</sub> +7.7 mL/year (95% CI 1.3 to 14.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0129" title="SinDD , WuL , AndersonJA , AnthonisenNR , BuistAS , BurgePS , et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax2005;60(12):992-7.">Sin 2005</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality HR 0.75 (95% CI 0.57 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individual participant data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0117" title="GartlehnerG , HansenRA , CarsonSS , LohrKN . Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Annals of Family Medicine2006;4(3):253-62.">Gartlehner 2006</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations RR 0.67 (95% CI 0.59 to 0.77)</p> <p>Mortality RR 0.81 (95% CI 0.60 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0131" title="SorianoJB , SinDD , ZhangX , AndersonJA , AnthonisenNR , BuistAS , et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest2007;131:682-9.">Soriano 2007</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of decline in postbronchodilator FEV<sub>1</sub> 0.01% (SD 0.09%) (P = 0.86) at 6–36 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individual participant data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0114" title="DrummondMB , DasenbrookEC , PitzMW , MurphyDJ , FanE . Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA2008;300(20):2407-16.">Drummond 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality RR 0.78 (95% CI 0.56 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICS monotherapy subgroup analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0114" title="DrummondMB , DasenbrookEC , PitzMW , MurphyDJ , FanE . Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA2008;300(20):2407-16.">Drummond 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia RR 1.06 (95% CI 0.67 to 1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICS monotherapy subgroup analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0130" title="SinghS , AminAV , LokeYK . Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Archives of Internal Medicine2009;169(3):219-29.">Singh 2009</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia RR 1.51 (95% CI 1.08 to 2.10)<br/>Mortality RR 1.01 (95% CI 0.87 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICS monotherapy subgroup analysis</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; FEV<sub>1</sub>: forced expiratory volume in one second; HR: hazard ratio; ICS: inhaled corticosteroid; RR: risk ratio; SD: standard deviation. </p> </div> </div> <p>Regarding potentially beneficial effects of ICS, some previous meta‐analyses, but not others, have shown effects on lung function decline. Our updated systematic review has now observed a benefit of ICS as monotherapy on the rate of decline in FEV<sub>1</sub>, although the magnitude of the change is numerically still relatively small. The reduction in exacerbation rate has been consistent and significant across the three versions of our systematic review, although the benefit remains a relatively small effect for ICS alone. The lack of effect on mortality has remained a consistent finding. </p> <p>Regarding adverse effects of ICS, one systematic review by Kew and colleagues on ICS (monocomponent or in combination) and pneumonia in people with COPD found that fluticasone increased pneumonia adverse events (OR 1.78, 95% CI 1.50 to 2.12), but without an increase in mortality (<a href="./references#CD002991-bbs2-0123" title="KewKM , SeniukovichA . Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD010115. [DOI: 10.1002/14651858.CD010115.pub2]">Kew 2014</a>). Further systematic reviews and meta‐analyses have reported an increase in pneumonia events with ICS (<a href="./references#CD002991-bbs2-0114" title="DrummondMB , DasenbrookEC , PitzMW , MurphyDJ , FanE . Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA2008;300(20):2407-16.">Drummond 2008</a>; <a href="./references#CD002991-bbs2-0130" title="SinghS , AminAV , LokeYK . Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Archives of Internal Medicine2009;169(3):219-29.">Singh 2009</a>), with evidence of a dose‐dependent relationship and increased risk associated with fluticasone compared to BUD preparations (<a href="./references#CD002991-bbs2-0125" title="MiravitllesM , Auladell-RispauA , MonteagudoM , Carlos Vázquez-NieblaJ , MohammedJ , NuñezA , et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. European Respiratory Review2021;30:210075. [DOI: 10.1183/16000617.0075-2021]">Miravitlles 2021</a>; <a href="./references#CD002991-bbs2-0136" title="YangM , DuY , ChenH , JiangD , XuZ . Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. International Immunopharmacology2019;77:105950. [DOI: doi.org/10.1016/j.intimp.2019.105950]">Yang 2019</a>; <a href="./references#CD002991-bbs2-0123" title="KewKM , SeniukovichA . Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD010115. [DOI: 10.1002/14651858.CD010115.pub2]">Kew 2014</a>). Variability in defining pneumonia in RCTs has been noted, with self‐reporting, clinical, radiographical or microbiological diagnoses being utilised across studies (<a href="./references#CD002991-bbs2-0123" title="KewKM , SeniukovichA . Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD010115. [DOI: 10.1002/14651858.CD010115.pub2]">Kew 2014</a>). Future studies should prospectively confirm the diagnosis of pneumonia using clinical and radiological evidence (<a href="./references#CD002991-bbs2-0134" title="WelteT . Inhaled corticosteroids in COPD and the risk of pneumonia. Lancet2009;374(9691):668-70. [1474-547X: (Electronic)]">Welte 2009</a>). </p> <p>This evidence summarised in our systematic review should be considered in the light of new studies of combination therapies, whilst keeping in mind the existing evidence for ICS alone. ICS targets the airway inflammation component of COPD but there remain other pathophysiological contributors such as small airway damage, alveolar abnormalities and hyperinflation that can be targeted by other therapies such as bronchodilators. ICS as monotherapy is not recommended by international guidelines but knowledge of the effects of ICS alone in multiple studies over many years remains valuable to summarise and interpret, in light of the current widespread use of ICS (in combination with long‐acting bronchodilators) in people with COPD. </p> <p>It is now much less likely that ICS as monotherapy (or placebo) will be included as treatment arms in future long‐term RCTs, since other comparators (long‐acting bronchodilators and their combinations, or ICS/LABA combinations) are more appropriate in terms of study design. Hence, we anticipate that future updates addressing evidence of ICS monotherapy vs placebo for COPD will not be required. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002991-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram. BHR: bronchial hyper‐responsiveness." data-id="CD002991-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram. BHR: bronchial hyper‐responsiveness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002991-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Figure 3: Forest plot (1.2 Exacerbation rate (mean difference))." data-id="CD002991-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Figure 3: Forest plot (1.2 Exacerbation rate (mean difference)).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Figure 3: Forest plot (1.2 Exacerbation rate)." data-id="CD002991-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Figure 3: Forest plot (1.2 Exacerbation rate).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot (1.8 Postbronchodilator FEV1 – Difference in rate of decline)." data-id="CD002991-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot (1.8 Postbronchodilator FEV<sub>1</sub> – Difference in rate of decline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot (1.9 Change in postbronchodilator FEV1 (mL/year)." data-id="CD002991-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot (1.9 Change in postbronchodilator FEV<sub>1</sub> (mL/year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot (1.7 Mortality)." data-id="CD002991-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot (1.7 Mortality).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 1: Exacerbation rate (number per participant per year)" data-id="CD002991-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 1: Exacerbation rate (number per participant per year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 2: Exacerbation rate ratio" data-id="CD002991-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 2: Exacerbation rate ratio </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 3: Number of participants with ≥ 1 exacerbation" data-id="CD002991-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 3: Number of participants with ≥ 1 exacerbation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 4: Total St George's Respiratory Questionnaire (SGRQ) score (units)" data-id="CD002991-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 4: Total St George's Respiratory Questionnaire (SGRQ) score (units) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 5: Change in SGRQ total score (units/year)" data-id="CD002991-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 5: Change in SGRQ total score (units/year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 6: Mean change in SGRQ – total scores" data-id="CD002991-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 6: Mean change in SGRQ – total scores </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 7: Mortality" data-id="CD002991-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 7: Mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 8: Postbronchodilator forced expiratory volume in one second (FEV1) – difference in rate of decline" data-id="CD002991-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 8: Postbronchodilator forced expiratory volume in one second (FEV<sub>1</sub>) – difference in rate of decline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 9: Change in postbronchodilator FEV1 (mL/year)" data-id="CD002991-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 9: Change in postbronchodilator FEV<sub>1</sub> (mL/year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 10: FEV1 (% change from baseline)" data-id="CD002991-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 10: FEV<sub>1</sub> (% change from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 11: Pneumonia" data-id="CD002991-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 11: Pneumonia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 12: Cough score" data-id="CD002991-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 12: Cough score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 13: Breathlessness score" data-id="CD002991-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 13: Breathlessness score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 14: Throat irritation (number of participants)" data-id="CD002991-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 14: Throat irritation (number of participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 15: Oropharyngeal candidiasis (number of participants)" data-id="CD002991-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 15: Oropharyngeal candidiasis (number of participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 16: Hoarseness or dysphonia (number of participants)" data-id="CD002991-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 16: Hoarseness or dysphonia (number of participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 17: Bruising (number of participants)" data-id="CD002991-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 17: Bruising (number of participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 18: Vertebral fractures (number of participants)" data-id="CD002991-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 18: Vertebral fractures (number of participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 19: Cataracts (number of participants)" data-id="CD002991-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 19: Cataracts (number of participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 20: Number of participants with serum cortisol below normal range at any time" data-id="CD002991-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 20: Number of participants with serum cortisol below normal range at any time </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 21: Any fractures (number of participants)" data-id="CD002991-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 21: Any fractures (number of participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 22: Sputum production score" data-id="CD002991-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 22: Sputum production score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 23: Sputum colour score" data-id="CD002991-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 23: Sputum colour score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 24: Number of participants with change from within to below normal for serum cortisol" data-id="CD002991-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: ICS versus placebo, parallel‐group studies, greater than 6 months (all doses), Outcome 24: Number of participants with change from within to below normal for serum cortisol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 1: Number of participants with ≥ 1 exacerbation" data-id="CD002991-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 1: Number of participants with ≥ 1 exacerbation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 2: Mean change in St George's Respiratory Questionnaire (SGRQ) – total scores" data-id="CD002991-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 2: Mean change in St George's Respiratory Questionnaire (SGRQ) – total scores </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 3: Change in prebronchodilator forced expiratory volume in one second (FEV1) compared with baseline" data-id="CD002991-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 3: Change in prebronchodilator forced expiratory volume in one second (FEV<sub>1</sub>) compared with baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 4: Change in postbronchodilator FEV1 compared to baseline (L)" data-id="CD002991-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 4: Change in postbronchodilator FEV<sub>1</sub> compared to baseline (L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 5: Postbronchodilator FEV1 (change from baseline)" data-id="CD002991-fig-0036" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 5: Postbronchodilator FEV<sub>1</sub> (change from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 6: Change in prebronchodilator FEV1 compared with baseline" data-id="CD002991-fig-0037" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 6: Change in prebronchodilator FEV<sub>1</sub> compared with baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 7: Total number of deaths" data-id="CD002991-fig-0038" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 7: Total number of deaths </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 8: Rescue beta‐agonist use (puffs/day)" data-id="CD002991-fig-0039" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 8: Rescue beta‐agonist use (puffs/day) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 9: 6‐minute walk (change scores)" data-id="CD002991-fig-0040" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 9: 6‐minute walk (change scores) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 10: Change in 6‐minute walk distance from baseline (m)" data-id="CD002991-fig-0041" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 10: Change in 6‐minute walk distance from baseline (m) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 11: Change from baseline in dyspnoea on CRQ (units)" data-id="CD002991-fig-0042" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 11: Change from baseline in dyspnoea on CRQ (units) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 12: Change from baseline in emotion on Chronic Respiratory Questionnaire (CRQ) (units)" data-id="CD002991-fig-0043" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 12: Change from baseline in emotion on Chronic Respiratory Questionnaire (CRQ) (units) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 13: Change from baseline in fatigue on CRQ" data-id="CD002991-fig-0044" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 13: Change from baseline in fatigue on CRQ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 14: Change from baseline in mastery on CRQ (units)" data-id="CD002991-fig-0045" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 14: Change from baseline in mastery on CRQ (units) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 15: Throat irritation (number of participants)" data-id="CD002991-fig-0046" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 15: Throat irritation (number of participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 16: Oropharyngeal candidiasis (number of participants)" data-id="CD002991-fig-0047" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 16: Oropharyngeal candidiasis (number of participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 17: Hoarseness or dysphonia (number of participants)" data-id="CD002991-fig-0048" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 17: Hoarseness or dysphonia (number of participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 18: Pneumonia (number of participants)" data-id="CD002991-fig-0049" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 18: Pneumonia (number of participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002991-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/urn:x-wiley:14651858:media:CD002991:CD002991-CMP-002.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 19: Number of participants with serum cortisol below normal range at any time" data-id="CD002991-fig-0050" src="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_t/tCD002991-CMP-002.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2: ICS versus placebo, parallel‐group studies, 3–6 months (all doses), Outcome 19: Number of participants with serum cortisol below normal range at any time </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/media/CDSR/CD002991/image_n/nCD002991-CMP-002.19.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002991-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ ICS compared to placebo for adults with stable chronic obstructive pulmonary disease in studies of greater than six months? duration</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ICS compared to placebo for adults with stable chronic obstructive pulmonary disease in studies of greater than six months' duration</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with stable chronic obstructive pulmonary disease<br/><b>Setting:</b> clinical practice/outpatient<br/><b>Intervention:</b> ICS<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ICS</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation rate (exacerbations per participant per year)<br/>follow‐up: mean 95 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean exacerbation rate (exacerbations per participant per year) was <b>0.60</b> exacerbations per patient per year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.05 exacerbations per patient per year lower</b><br/>(0.07 lower to 0.02 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10316<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Of clinical relevance</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (mean change in SGRQ score)<br/>follow‐up: mean 77 weeks<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life (mean change in SGRQ score) was <b>‐0.11</b> points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>1.22 points lower</b><br/>(1.83 lower to 0.6 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2507<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Of uncertain clinical relevance (minimal clinically important difference 4). SGRQ: St George's Respiratory Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in postbronchodilator FEV1 (mL/year)<br/>follow‐up: mean 118 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in postbronchodilator FEV1 (mL/year) was <b>‐49.01</b> mL/year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>7.28 mL/year lower</b><br/>(3.21 lower to 11.35 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12502<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Of uncertain clinical relevance. FEV1: forced expiratory volume in 1 second.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality<br/>follow‐up: mean 113 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b><br/>(61 to 77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.94</b><br/>(0.84 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16636<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not of clinical relevance</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia<br/>follow‐up: mean 106 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>84 per 1000</b><br/>(63 to 111) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.38</b><br/>(1.02 to 1.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14831<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Of clinical relevance</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oropharyngeal candidiasis<br/>follow‐up: mean 114 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b><br/>(37 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.66</b><br/>(1.91 to 3.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5547<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Of clinical relevance</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_428279190022928617" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_428279190022928617</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for imprecision; wide 95% confidence intervals encompassing no effect, benefit and risk.<br/><sup>b</sup> St George's Respiratory Questionnaire (SGRQ) scale from 0 to 100 with higher scores indicating greater impact on health, function and quality of life.<br/><sup>c</sup> Downgraded one level for inconsistency; moderate heterogeneity (overall I2 = 55%) noting that effect sizes were similar between studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ ICS compared to placebo for adults with stable chronic obstructive pulmonary disease in studies of greater than six months? duration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002991-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Search history detail</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Year</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Abstracts retrieved</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to and including 1999</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1340</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009–2010</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012–2013</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2015–2016</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2017</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2018</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2019–2021</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>625</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2021 to 31 October 2022</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>324</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Search history detail</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002991-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Published meta‐analyses of ICS versus placebo for stable chronic obstructive pulmonary disease</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Reference</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Year</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Results for ICS as monocomponent (compared to placebo)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0133" title="vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax1999;54(1):7-14. [DOI: 10.1136/thx.54.1.7]">van Grunsven 1999</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of decline in prebronchodilator FEV<sub>1</sub> +34 mL/year (95% CI 5 to 63)<br/>No difference in exacerbation rate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data included in this current review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0121" title="HighlandKB , StrangeC , HeffnerJE . Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: a meta-analysis. Annals of Internal Medicine2003;138(12):969-73.">Highland 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of decline in pre‐ or postbronchodilator FEV<sub>1</sub> +5.31 (SD 3.0) mL/year (P = 0.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0132" title="SutherlandER , AllmersH , AyasNT , VennAJ , MartinRJ . Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax2003;58(11):937-41.">Sutherland 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of decline in postbronchodilator FEV<sub>1</sub> +7.7 mL/year (95% CI 1.3 to 14.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0129" title="SinDD , WuL , AndersonJA , AnthonisenNR , BuistAS , BurgePS , et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax2005;60(12):992-7.">Sin 2005</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality HR 0.75 (95% CI 0.57 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individual participant data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0117" title="GartlehnerG , HansenRA , CarsonSS , LohrKN . Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Annals of Family Medicine2006;4(3):253-62.">Gartlehner 2006</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations RR 0.67 (95% CI 0.59 to 0.77)</p> <p>Mortality RR 0.81 (95% CI 0.60 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0131" title="SorianoJB , SinDD , ZhangX , AndersonJA , AnthonisenNR , BuistAS , et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest2007;131:682-9.">Soriano 2007</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of decline in postbronchodilator FEV<sub>1</sub> 0.01% (SD 0.09%) (P = 0.86) at 6–36 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individual participant data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0114" title="DrummondMB , DasenbrookEC , PitzMW , MurphyDJ , FanE . Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA2008;300(20):2407-16.">Drummond 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality RR 0.78 (95% CI 0.56 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICS monotherapy subgroup analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0114" title="DrummondMB , DasenbrookEC , PitzMW , MurphyDJ , FanE . Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA2008;300(20):2407-16.">Drummond 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia RR 1.06 (95% CI 0.67 to 1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICS monotherapy subgroup analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002991-bbs2-0130" title="SinghS , AminAV , LokeYK . Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Archives of Internal Medicine2009;169(3):219-29.">Singh 2009</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia RR 1.51 (95% CI 1.08 to 2.10)<br/>Mortality RR 1.01 (95% CI 0.87 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICS monotherapy subgroup analysis</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval; FEV<sub>1</sub>: forced expiratory volume in one second; HR: hazard ratio; ICS: inhaled corticosteroid; RR: risk ratio; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Published meta‐analyses of ICS versus placebo for stable chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/full#CD002991-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002991-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ICS versus placebo, parallel‐group studies, greater than 6 months (all doses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Exacerbation rate (number per participant per year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.07, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.07, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.31, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Exacerbation rate ratio <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.82, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.81, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.79, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Number of participants with ≥ 1 exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.72, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.68, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.63, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Total St George's Respiratory Questionnaire (SGRQ) score (units) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Change in SGRQ total score (units/year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Mean change in SGRQ – total scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Units on SGRQ scale (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.22 [‐1.83, ‐0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Units on SGRQ scale (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.22 [‐1.83, ‐0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16636</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.75, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.85, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Postbronchodilator forced expiratory volume in one second (FEV<sub>1</sub>) – difference in rate of decline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>mL/year (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.31 [1.76, 10.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>mL/year (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.83 [0.90, 10.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>mL/year (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.00 [‐2.76, 20.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Change in postbronchodilator FEV<sub>1</sub> (mL/year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.28 [3.21, 11.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.11 [0.11, 10.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.58 [4.57, 18.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 FEV<sub>1</sub> (% change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>% (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>% (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.02, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.69, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.37, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Cough score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>739</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.14, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Breathlessness score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>739</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.16, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Throat irritation (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.29, 2.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.29, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.00, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Oropharyngeal candidiasis (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.66 [1.91, 3.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.22 [1.88, 5.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.56 [1.48, 4.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Hoarseness or dysphonia (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.44, 2.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.16, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [1.38, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Bruising (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4778</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.33, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.41, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1932</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.01, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Vertebral fractures (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Cataracts (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.79, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.81, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.34, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Number of participants with serum cortisol below normal range at any time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Any fractures (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.81, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.76, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.73, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Sputum production score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Sputum colour score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Number of participants with change from within to below normal for serum cortisol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ICS versus placebo, parallel‐group studies, greater than 6 months (all doses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002991-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ICS versus placebo, parallel‐group studies, 3–6 months (all doses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Number of participants with ≥ 1 exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.68, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.68, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Mean change in St George's Respiratory Questionnaire (SGRQ) – total scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Change in prebronchodilator forced expiratory volume in one second (FEV<sub>1</sub>) compared with baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.02, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.04, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Change in postbronchodilator FEV<sub>1</sub> compared to baseline (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.01, 0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.03, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.08, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Postbronchodilator FEV<sub>1</sub> (change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Litres (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.05, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Litres (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.08, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Litres (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.06, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Change in prebronchodilator FEV<sub>1</sub> compared with baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Litres (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.02, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Litres (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.00, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Litres (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.02, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Total number of deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.05, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.05, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Rescue beta‐agonist use (puffs/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 6‐minute walk (change scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Metres (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Metres (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Change in 6‐minute walk distance from baseline (m) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.36 [‐50.42, 41.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.36 [‐50.42, 41.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Change from baseline in dyspnoea on CRQ (units) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Change from baseline in emotion on Chronic Respiratory Questionnaire (CRQ) (units) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Change from baseline in fatigue on CRQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Change from baseline in mastery on CRQ (units) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Throat irritation (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.80, 2.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.65, 3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.41, 5.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Oropharyngeal candidiasis (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2928</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.91 [1.67, 9.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [0.70, 11.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.92 [1.50, 16.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Hoarseness or dysphonia (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.56 [1.74, 7.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.32 [1.06, 10.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.73 [1.49, 9.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Pneumonia (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.76, 5.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.1 &lt; BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.47, 4.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.2 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.47 [0.69, 29.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.19 Number of participants with serum cortisol below normal range at any time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.1 ≥ BDP 1000 µg equivalent/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ICS versus placebo, parallel‐group studies, 3–6 months (all doses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002991.pub4/references#CD002991-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002991.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD002991-note-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD002991-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002991-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002991-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD002991-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD002991-note-0011">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ko#CD002991-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD002991-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD002991-note-0014">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002991-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002991-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002991\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002991\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002991\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002991\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002991\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002991.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002991.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002991.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002991.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002991.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715143917"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002991.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715143921"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002991.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7fe7fe701bde',t:'MTc0MDcxNTE0NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 